<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006868.pub2" GROUP_ID="SCHIZ" ID="335107030615555757" MERGED_FROM="" MODIFIED="2013-10-02 15:40:45 +0100" MODIFIED_BY="Claire Irving" REVIEW_NO="" REVMAN_SUB_VERSION="5.2.6 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2013-10-02 15:40:45 +0100" MODIFIED_BY="Claire Irving">
<TITLE>Dance therapy for schizophrenia</TITLE>
<CONTACT MODIFIED="2013-10-02 15:40:45 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="16631181790061539774120718130251" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Juanjuan</FIRST_NAME><LAST_NAME>Ren</LAST_NAME><POSITION>Research Assistant</POSITION><EMAIL_1>juanerren@126.com</EMAIL_1><ADDRESS><DEPARTMENT>Biological Psychiatry</DEPARTMENT><ORGANISATION>Shanghai Mental Health Center</ORGANISATION><ADDRESS_1>600 Wan Ping Nan Road</ADDRESS_1><CITY>Shanghai</CITY><ZIP>200030</ZIP><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>(8621)-64387250 ext. 73310</PHONE_1><FAX_1>(8621)-64387986</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-10-02 15:40:45 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="16631181790061539774120718130251" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Juanjuan</FIRST_NAME><LAST_NAME>Ren</LAST_NAME><POSITION>Research Assistant</POSITION><EMAIL_1>juanerren@126.com</EMAIL_1><ADDRESS><DEPARTMENT>Biological Psychiatry</DEPARTMENT><ORGANISATION>Shanghai Mental Health Center</ORGANISATION><ADDRESS_1>600 Wan Ping Nan Road</ADDRESS_1><CITY>Shanghai</CITY><ZIP>200030</ZIP><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>(8621)-64387250 ext. 73310</PHONE_1><FAX_1>(8621)-64387986</FAX_1></ADDRESS></PERSON><PERSON ID="258C268D82E26AA2000C5DBBFFD4E447" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Jun</FIRST_NAME><LAST_NAME>Xia</LAST_NAME><POSITION>Research Associate</POSITION><EMAIL_1>Jun.Xia@nottingham.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Cochrane Schizophrenia Group</DEPARTMENT><ORGANISATION>The University of Nottingham</ORGANISATION><ADDRESS_1>Institute of Mental Health</ADDRESS_1><ADDRESS_2>University of Nottingham Innovation Park, Triumph Road,</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2TU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 113 8550686</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-06-18 13:58:59 +0100" MODIFIED_BY="Bethany York">
<UP_TO_DATE>
<DATE DAY="10" MONTH="7" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="10" MONTH="7" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="24" MONTH="12" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2013-10-02 15:08:14 +0100" MODIFIED_BY="Claire Irving">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-10-02 15:08:14 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="2" MONTH="10" YEAR="2013"/>
<DESCRIPTION>
<P>Update completed: no new included studies, conclusions not changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-06-27 08:40:39 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="6" YEAR="2013"/>
<DESCRIPTION>
<P>Results from update searching added to review, no new included studies.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-06-18 14:06:41 +0100" MODIFIED_BY="Claire Irving">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-06-18 14:06:41 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="7" YEAR="2012"/>
<DESCRIPTION>
<P>Update search of Cochrane Schizophrenia Group's Trial Register (see <A HREF="http://archie.cochrane.org/sections/documents/view?version=44705070754671417758120516110605&amp;format=REVMAN#SEARCH_METHODS">Search methods for identification of studies</A>), one study added to awaiting classification.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-07-11 15:21:16 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="10" YEAR="2011"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-10-05 15:43:44 +0100" MODIFIED_BY="Claire Irving">
<DATE DAY="19" MONTH="1" YEAR="2011"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-01-19 20:09:54 +0000" MODIFIED_BY="Claire Irving">
<DATE DAY="10" MONTH="11" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-11-10 14:27:01 +0000" MODIFIED_BY="Claire Irving">
<DATE DAY="11" MONTH="11" YEAR="2009"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-11-11 10:36:26 +0000" MODIFIED_BY="Claire Irving">
<DATE DAY="20" MONTH="7" YEAR="2009"/>
<DESCRIPTION>
<P>Plain Language Summary added</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2008-11-11 16:59:11 +0000" MODIFIED_BY="Lelia Duley">
<INTERNAL_SOURCES MODIFIED="2008-11-11 16:59:11 +0000" MODIFIED_BY="Lelia Duley">
<SOURCE MODIFIED="2008-11-11 16:58:50 +0000" MODIFIED_BY="Lelia Duley">
<NAME>University of Leeds</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2008-11-11 16:59:11 +0000" MODIFIED_BY="Lelia Duley">
<NAME>University of Nottingham</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2008-10-03 15:01:33 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2008-10-03 15:01:33 +0100" MODIFIED_BY="[Empty name]">
<NAME>No external support received</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-10-02 15:24:36 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-10-02 15:15:56 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2013-02-25 14:27:15 +0000" MODIFIED_BY="[Empty name]">Dance therapy for schizophrenia</TITLE>
<SUMMARY_BODY MODIFIED="2013-10-02 15:15:56 +0100" MODIFIED_BY="[Empty name]">
<P>For previous PLS see <A HREF="01">Appendix 1</A>.</P>
<P>The first line of treatment of schizophrenia is usually antipsychotic drugs. Usually, these drugs are more effective in treating the 'positive symptoms' than 'negative symptoms' of schizophrenia. Moreover, antipsychotic drugs have debilitating side-effects such as weight gain, shaking, tremors and muscle stiffness. </P>
<P>Dance therapy (also known as dance movement therapy, DMT) uses movement and dance to explore a person&#8217;s emotions in a non-verbal way (without language or words). The therapist helps the individual to interpret their dance and movement and link them with people&#8217;s personal feelings. Dance has been used as a healing ritual since earliest human history, but the establishment of dance therapy as a profession is quite recent. Dance therapy can be used with people of all ages, races and genders. It can be effective in the treatment of people with medical, social, developmental, physical and psychological impairments. The review included one study with 45 participants. The aim was to compare dance therapy with standard care or other interventions. The one included study compared dance therapy plus routine care with routine care alone. In the main, there was no difference between those who engaged in dance therapy versus those who did not (for outcomes such as satisfaction with care, mental state, leaving the study early, quality of life). However, those who engaged in dance therapy showed significant improvement in negative symptoms. </P>
<P>Overall, because of the small number of participants, the findings are limited. There is little evidence to support or refute the use of dance therapy.  Larger studies and trials are needed that focus on important outcomes (such as rates of relapse, quality of life, admission to hospital, leaving the study early, cost of care and satisfaction with treatment). Further research would help clarify whether dance therapy is an effective and holistic treatment for people with schizophrenia, especially in terms of helping people cope with negative symptoms that do not respond so well to antipsychotic drugs.        </P>
<P>This summary was written by a consumer Ben Gray (Benjamin Gray, Service User and Service User Expert <A HREF="http://www.rethink.org/">Rethink Mental Illness</A>, Email: <A HREF="mailto:ben.gray@rethink.org">ben.gray@rethink.org</A>).</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-10-02 15:15:56 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-07-30 13:27:28 +0100" MODIFIED_BY="Lelia Duley">
<P>Dance therapy or dance movement therapy (DMT) is defined as 'the psychotherapeutic use of movement as a process which furthers the emotional, social, cognitive, and physical integration of the individual'. It may be of value for people with developmental, medical, social, physical or psychological impairments. Dance therapy can be practiced in mental health rehabilitation units, nursing homes, day care centres and incorporated into disease prevention and health promotion programmes.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-11-11 15:52:59 +0000" MODIFIED_BY="Lelia Duley">
<P>To evaluate the effects of dance therapy for people with schizophrenia or schizophrenia-like illnesses compared with standard care and other interventions.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-06-18 14:02:35 +0100" MODIFIED_BY="Lelia Duley">
<P>We updated the original July 2007 search of the Cochrane Schizophrenia Group' register in July 2012. We also searched Chinese main medical databases.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-10-02 15:15:56 +0100" MODIFIED_BY="[Empty name]">
<P>We included one randomised controlled trial (RCT) comparing dance therapy and related approaches with standard care or other psychosocial interventions for people with schizophrenia.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-10-02 15:15:56 +0100" MODIFIED_BY="[Empty name]">
<P>We reliably selected, quality assessed and extracted data. For continuous outcomes, we calculated a mean difference (MD); for binary outcomes we calculated a fixed-effect risk ratio (RR) and their 95% confidence intervals (CI). We created a 'Summary of findings' table using the GRADE approach.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-10-02 15:15:56 +0100" MODIFIED_BY="[Empty name]">
<P>We included one single blind study (total n = 45) of reasonable quality. It compared dance therapy plus routine care with routine care alone. Most people tolerated the treatment package but nearly 40% were lost in both groups by four months (1 RCT n = 45, RR 0.68 95% CI 0.31 to 1.51, <I>low quality evidence</I>). The Positive and Negative Syndrome Scale (PANSS) average endpoint total scores were similar in both groups (1 RCT n = 43, MD -0.50 95% CI -11.80 to 10.80, <I>moderate quality evidence</I>) as were the positive sub-scores (1 RCT n = 43, MD 2.50 CI -0.67 to 5.67, <I>moderate quality evidence</I>). At the end of treatment, significantly more people in the dance therapy group had a greater than 20% reduction in PANSS negative symptom score (1 RCT n = 45, RR 0.62 CI 0.39 to 0.97, <I>moderate quality evidence</I>), and overall, average negative endpoint scores were lower (1 RCT n = 43, MD -4.40 CI -8.15 to -0.65, <I>moderate quality evidence</I>). There was no difference in satisfaction score (average Client's Assessment of Treatment Scale (CAT) score, 1 RCT n = 42, MD 0.40 CI -0.78 to 1.58, <I>moderate quality evidence</I>) and quality of life data were also equivocal (average Manchester Short Assessment of Quality of life (MANSA) score, 1 RCT n = 39, MD 0.00 CI -0.48 to 0.48, <I>moderate quality evidence</I>). </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-09-23 16:47:50 +0100" MODIFIED_BY="Lelia Duley">
<P>Based on predominantly moderate quality data, there is no evidence to support - or refute - the use of dance therapy in this group of people. This therapy remains unproven and those with schizophrenia, their carers, trialists and funders of research may wish to encourage future work to increase high quality evidence in this area.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-10-02 15:22:40 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-10-02 15:15:56 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2008-11-12 12:05:29 +0000" MODIFIED_BY="[Empty name]">
<P>Schizophrenia is a chronic, severe and disabling illness which affects approximately 1% of the population. It is a worldwide illness that crosses all cultures and socioeconomic groups (<LINK REF="REF-Fortinash-2000" TYPE="REFERENCE">Fortinash 2000</LINK>). The severe and long-lasting symptoms of schizophrenia cause considerable disability.</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-10-02 15:15:56 +0100" MODIFIED_BY="[Empty name]">
<P>Dance has been used as a healing ritual since earliest human history, but the establishment of dance therapy as a profession is relatively recent (<LINK REF="REF-Chodorow-1991" TYPE="REFERENCE">Chodorow 1991</LINK>). Dance therapy is also sometimes referred to as dance movement therapy (DMT) (<LINK REF="REF-Payne-2006" TYPE="REFERENCE">Payne 2006</LINK>). It is informed by contemporary psychological and psychotherapeutic theories, body psychotherapy and multicultural trends in dance (<LINK REF="REF-Payne-2006" TYPE="REFERENCE">Payne 2006</LINK>). According to the American Dance Therapy Association (<A HREF="http://www.adta.org/">ADTA</A>), dance therapy can be used with people of all ages, race or ethnic background in the form of individual or group therapy (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). It is said to be effective in the treatment of people with developmental, medical, social, physical and psychological impairments. It can be practiced in various settings, such as mental health rehabilitation, medical, educational, forensic, nursing homes, day care, disease prevention and health promotion programs.</P>
<P>There is, however, no special therapeutic dance. Dance only becomes therapeutic in the hands of a specialist or therapist (<LINK REF="REF-Exiner-1994" TYPE="REFERENCE">Exiner 1994</LINK>). Therapeutic dance in any situation or with any population involves thinking, feeling and willing. The treatment approach is individualised, for example, duration of treatment sessions can vary from 20 minutes to 90 minutes depending on the individual client's frustration and tolerance levels. According to <LINK REF="REF-Exiner-1994" TYPE="REFERENCE">Exiner 1994</LINK>, the model of a dance therapy session commonly involves the following phases: entry, exploration, core action, review and conclusion. Participants tune up at entry stage and prepare their body for action. Then the movements that arise during the entry phase are experimented with in the exploration phase. Some of the physically beneficial and emotionally significant movements are then selected to be taken through to the core action phase and become themes. Movements are refined at core action phase and close attention is paid to its psycho-physical contents. Recognition of further therapeutic steps is also developed through this process. Before concluding the sessions, a review of the material is usually arranged. The therapist decides with participants what would be valuable for them to take away.</P>
</INTERVENTION>
<THEORY MODIFIED="2013-10-02 15:15:56 +0100" MODIFIED_BY="[Empty name]">
<P>The American Dance Therapy Association (<A HREF="http://www.adta.org">ADTA</A>) defines dance therapy as "the psychotherapeutic use of movement as a process which furthers the emotional, social, cognitive, and physical integration of the individual". <LINK REF="REF-Payne-2006" TYPE="REFERENCE">Payne 2006</LINK> notes that the principle of dance therapy is based on the assumption that motion and emotion are in reciprocal interaction. Through this relationship as a channel, one can embody a deeper connection with oneself. From a therapeutic point of view, there are a number of factors that make dance therapy particularly appropriate for use as therapeutic tool. Firstly, through body movement dance stimulates and releases feelings. Secondly, dance enables the person to release communications and contact non-verbally. Thirdly, the non-critical therapeutic setting often leads to reduction of anxiety. Fourthly, free movements with rhythm together create joy, both physically and emotionally. Finally, humans' natural responses to rhythm promote both individual movement and participatory behaviour of a group (<LINK REF="REF-Espenak-1981" TYPE="REFERENCE">Espenak 1981</LINK>). From a technical point of view, the foundation of dance therapy is 'the physical phenomena that provokes the occurrence of the emotion'. The therapist learns to interpret the client's motor expression and to relate their personal movements to personal feelings, and then reach the feeling through opportunities for experience in movement.</P>
</THEORY>
<IMPORTANCE MODIFIED="2008-11-12 12:19:09 +0000" MODIFIED_BY="[Empty name]">
<P>Dance therapy has been offered in a range of different settings for people with schizophrenia. Its efficacy as a therapy for this group of people, however, has yet to be determined.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-11-11 15:53:19 +0000" MODIFIED_BY="Lelia Duley">
<P>To evaluate the effects of dance therapy for people with schizophrenia or schizophrenia-like illnesses compared with standard care and other interventions.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-10-02 15:21:06 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-10-02 15:15:56 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-10-02 15:15:56 +0100" MODIFIED_BY="[Empty name]">
<P>All relevant randomised controlled trials. We excluded quasi-randomised studies, such as those where allocation is undertaken on surname. If a trial was described as double blind, but it was implied it had been randomised, we planned to include it in a sensitivity analysis.</P>
<P>We intended that if there was no substantive difference within primary outcomes (see '<LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>') when implied randomised trials were added, then we would include these trials in the final analysis. If there was a substantial difference, we would only analyse clearly randomised trials and describe the results of the sensitivity analysis in the text.</P>
<P>Randomised cross-over studies were eligible for inclusion but only data up to the point of first cross-over would have been used because of the instability of the problem behaviours and the likely carry-over effects of all treatments.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-10-02 15:15:56 +0100" MODIFIED_BY="Heather Maxwell">
<P>People with schizophrenia or where the majority (80%) of people in the study were likely to suffer from schizophrenia. In studies where non-specific labels were used, such as "chronic serious mental illness" we would have assumed that most people suffered from schizophrenia. We would not have been concerned how the diagnosis was made and we planned to include trials diagnosing people by any criteria, irrespective of gender, age or nationality.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-10-02 15:15:56 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Dance Therapy</HEADING>
<P>Dance therapy (in groups or individually), for any length of time, as an adjunctive treatment for schizophrenia or schizophrenia-like disorders, regardless of any other biological, psychological or social intervention being used.</P>
<P>We employed The American Dance Therapy Association's (<A HREF="http://www.adta.org/">ADTA</A>) definition of dance therapy - "the psychotherapeutic use of movement as a process which furthers the emotional, social, cognitive, and physical integration of the individual"<I> - </I>as a standard for inclusion, however, we did not need the therapy to be formally stated as dance therapy, for example, it may be stated as body-oriented psychological therapy (BPT). We considered any intervention using dance or movement as a therapeutic tool.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Standard/routine care</HEADING>
<P>The care that a person with schizophrenia would normally receive had they not been included in the research trial. We considered 'waiting list control groups' as standard care.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Other treatments</HEADING>
<P>These include any other biological, psychological or social treatments such as medication, problem-solving therapy, psycho-education programmes, social skills training, cognitive-behavioural therapy, family therapy or psychodynamic psychotherapy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Non intervention</HEADING>
<P>Untreated control groups.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-10-02 15:15:56 +0100" MODIFIED_BY="Lelia Duley">
<P>We divided outcomes into short term (less than one month) medium term (one month - three months) and long term (more than three months).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-09-23 11:33:16 +0100" MODIFIED_BY="Lelia Duley">
<SUBSECTION>
<HEADING LEVEL="5">1. Service utilisation</HEADING>
<P>1.1 Days in hospital - medium term</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Clinical global response</HEADING>
<P>2.1 Relapse - medium term<BR/>
</P>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-10-02 15:15:56 +0100" MODIFIED_BY="Lelia Duley">
<SUBSECTION>
<HEADING LEVEL="5">1. Service utilisation</HEADING>
<P>1.1 Hospital admission<BR/>1.2 Days in hospital - other than medium term</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Clinical global response</HEADING>
<P>2.1 Global state - not improved<U>
<BR/>
</U>2.2 Relapse - other than medium term<U>
<BR/>
</U>2.3 Average change or endpoint score in global state<BR/>2.4 Leaving the study early<BR/>2.5 Compliance with medication</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Mental state</HEADING>
<P>3.1 Positive symptoms (delusions, hallucinations, disordered thinking)<BR/>3.2 Negative symptoms (avolition, poor self-care, blunted affect)<BR/>3.3 No clinically important change in specific symptoms<BR/>3.4 Average change or endpoint score</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Social functioning</HEADING>
<P>4.1 Average change or endpoint scores<BR/>4.2 Social impairment<BR/>4.3 Employment status (employed/unemployed)<BR/>4.4 Work-related activities<BR/>4.5 Unable to live independently</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Quality of life</HEADING>
<P>5.1 No clinically important change in quality of life<BR/>5.2 Not any change in quality of life<BR/>5.3 Average change or endpoint scores<BR/>5.4 No clinically important change in specific aspects of quality of life<BR/>5.5 Not any change in specific aspects of quality of life<BR/>5.6 Average change or endpoint scores</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6. Family outcome</HEADING>
<P>6.1 Average score/change in family burden<BR/>6.2 Patient and family coping abilities<BR/>6.3 Understanding of the family member with schizophrenia<BR/>6.4 Family care and maltreatment of the person with schizophrenia<BR/>6.5 Expressed emotion<BR/>6.6 Quality of life/satisfaction with care for either recipients of care or their carers<BR/>6.7 Economic outcomes<BR/>6.8 Cost of care</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7. Satisfaction with treatment</HEADING>
<P>7.1 Recipient of treatment not satisfied with therapy<BR/>7.2 Recipient of treatment average satisfaction score<BR/>7.3 Recipient of treatment average change in satisfaction scores<BR/>7.4 Carer not satisfied with treatment<BR/>7.5 Carer average satisfaction score<BR/>7.6 Carer average change in satisfaction score</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8. Adverse effects/events</HEADING>
<P>8.1 No clinically important general adverse effects<BR/>8.2 Not any general adverse effects<BR/>8.3 Average change or endpoint general adverse effect scores<BR/>8.4 No clinically important change in specific adverse effect<BR/>8.5 Not any change in specific adverse effects<BR/>8.6 Average change or endpoint specific adverse effects<BR/>8.7 Suicide and all causes of mortality</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">9. 'Summary of findings' table</HEADING>
<P>We used the <A HREF="http://www.ims.cochrane.org/revman/gradepro">GRADE</A> approach to interpret findings (<LINK REF="REF-Sch_x00fc_nemann-2008" TYPE="REFERENCE">Schünemann 2008</LINK>) and used the GRADE profiler to import data from Review Manager (<A HREF="http://www.ims.cochrane.org/revman">RevMan</A>) to create 'Summary of findings' tables. These tables provide outcome-specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient-care and decision making. We selected the following main outcomes for inclusion in the <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1. Service utilisation</HEADING>
<P>1.1 days in hospital - medium term</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Clinical global response</HEADING>
<P>2.1 relapse - medium term<BR/>2.2 leaving the study early - short term and long term</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Mental state</HEADING>
<P>3.1 no clinically important change in specific symptoms<BR/>3.2 positive symptoms and negative symptoms endpoint score</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Satisfaction with treatment</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Quality of life</HEADING>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-10-02 15:15:56 +0100" MODIFIED_BY="Lelia Duley">
<P>For previous search strategy please see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<ELECTRONIC_SEARCHES MODIFIED="2013-10-02 15:15:56 +0100" MODIFIED_BY="Lelia Duley">
<SUBSECTION>
<HEADING LEVEL="4">Updated search(2012)</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1. Cochrane Schizophrenia Group Trials Register (July 2012)</HEADING>
<P>The Trials Search Co-ordinator searched the Cochrane Schizophrenia Group&#8217;s Trials Register (10th July 2012)</P>
<P>The &#8216;Intervention&#8217; field was searched using the phrase:</P>
<P>*danc*</P>
<P>The Cochrane Schizophrenia Group&#8217;s Trials Register is compiled by systematic searches of major databases, handsearches of journals and conference proceedings (see <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html">Group Module</A>). Incoming trials are screened by the Trial Search Co-ordinator and assigned to relevant existing or new review titles.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Chinese main medical databases (1 January 2007 to 17 September 2012)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Chongqing VIP Database (VIP)</HEADING>
<P>(R=&#38543;&#26426;+&#23545;&#29031;+&#23545;&#27604;+&#27604;&#36739;+&#30450;&#27861;)*(R=&#20998;&#35010;&#30151;+&#31934;&#31070;&#30149;+&#20998;&#35010;&#26679;+&#31934;&#31070;&#20998;&#35010;)*(R=(&#33310;&#36424;+&#36339;&#33310;+&#36816;&#21160;+&#21160;&#20316;)) (note: R abstract, '+' OR, '*' and)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 WANFANG Database</HEADING>
<P>((abstract:&#38543;&#26426;) or (abstract:&#23545;&#29031;) or (abstract:&#23545;&#27604;) or (abstract:&#27604;&#36739;) or (abstract:&#30450;&#27861;)) ((abstract:&#20998;&#35010;&#30151;) or (abstract:&#31934;&#31070;&#20998;&#35010;) or (abstract:&#31934;&#31070;&#30149;)or(abstract:&#20998;&#35010;&#26679;)) ((abstract:&#33310;&#36424;) or (abstract:&#36339;&#33310;) or (abstract:&#21160;&#20316;) or (abstract:&#36816;&#21160;))</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3 China National Knowledge Infrastructure (CNKI)</HEADING>
<P>(AB=&#38543;&#26426;+&#23545;&#29031;+&#23545;&#27604;+&#27604;&#36739;+&#30450;&#27861;) and (AB=&#20998;&#35010;&#30151;+&#31934;&#31070;&#20998;&#35010;+&#20998;&#35010;&#26679;+&#31934;&#31070;&#30149;) and (AB=&#36339;&#33310;+&#33310;&#36424;+&#36816;&#21160;+&#21160;&#20316;) (note: AB abstract, '+' OR )</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4 Chinese biomedicine Database (CBM-disk)</HEADING>
<P>((abstract:&#38543;&#26426; or abstract:&#23545;&#29031; or abstract:&#23545;&#27604; or abstract:&#27604;&#36739; or abstract:&#30450;&#27861;) and (abstract:&#20998;&#35010;&#30151; or abstract:&#31934;&#31070;&#20998;&#35010; or abstract:&#31934;&#31070;&#30149; or abstract:&#20998;&#35010;&#26679;)) and (abstract:&#33310;&#36424; or abstract:&#36339;&#33310; or abstract:&#36816;&#21160; or abstract:&#21160;&#20316;)<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-10-02 15:15:56 +0100" MODIFIED_BY="[Empty name]">
<P>We inspected references of all identified studies (included and excluded) for further relevant trials. We also contacted the first authors of the one included study for information regarding unpublished trials and, if necessary, extra data on the published trial.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-10-02 15:21:06 +0100" MODIFIED_BY="[Empty name]">
<P>For previous data collection and analyses please see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.<BR/>
</P>
<STUDY_SELECTION MODIFIED="2013-10-02 15:15:56 +0100" MODIFIED_BY="[Empty name]">
<P>Review authors (JR and JX) independently inspected citations identified in the search. After identifying potentially relevant abstracts we ordered full papers. JX re-inspected a random 10% to ensure reliable selection. Once the full papers had been obtained JR and JX decided if they met the review inclusion criteria. We resolved disputes over whether studies met the inclusion criteria by discussion, but if we had been unable to reach agreement, we planned to addthese trials to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK> until further information became available.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-10-02 15:20:30 +0100" MODIFIED_BY="Lelia Duley">
<SUBSECTION>
<HEADING LEVEL="4">1. Extraction</HEADING>
<P>For this update, JR and JX extracted data from the included study. We extracted data presented only in graphs and figures where possible. When further information was necessary, we contacted the authors of the study in order to obtain missing data or for clarification. If we had identified studies that were multicentre, where possible, we planned to extract the data relevant to each component centre separately.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Management</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Forms</HEADING>
<P>We extracted data onto standard, simple forms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Scale-derived data</HEADING>
<P>We included continuous data from rating scales only if:<BR/>a. the psychometric properties of the measuring instrument have been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>); and<BR/>b. the measuring instrument has not been written or modified by one of the trialists for that particular trial.</P>
<P>Ideally, the measuring instrument should either be i. a self-report or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly; we have noted whether or not this is the case in <LINK TAG="STUDY_DESCRIPTION" TYPE="SECTION">Description of studies</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3 Endpoint versus change data</HEADING>
<P>There are advantages of both endpoint and change data. Change data can remove a component of between-person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult to measure conditions such as schizophrenia. We decided primarily to use endpoint data, and only use change data if the former were not available. Only one trial was included, therefore, we were unable to combine data. If in future updates of this review, we identify more trials, we will combine endpoint and change data in the analysis using mean differences (MD) rather than standardised mean differences throughout (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>, Chapter 9.4.5.2).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4 Skewed data</HEADING>
<P>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we aimed to apply the following standards to all data before inclusion:</P>
<P>a) standard deviations (SDs) and means are reported in the paper or obtainable from the authors;</P>
<P>b) when a scale starts from the finite number zero, the SD, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>));</P>
<P>c) if a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS, <LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>), which can have values from 30 to 210), we modified the calculation described above to take the scale starting point into account. In these cases skew is present if 2 SD &gt; (S-S min), where S is the mean score and S min is the minimum score.</P>
<P>Endpoint scores on scales often have a finite start and end point and these rules can be applied. We entered skewed endpoint data from studies of fewer than 200 participants as 'other data' within the data and analyses rather than into a statistical analysis. Skewed data pose less of a problem when looking at the mean if the sample size is large; we would have entered such endpoint data into syntheses.</P>
<P>When continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not, we entered skewed change data into analyses regardless of size of study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5 Common measure</HEADING>
<P>To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6 Conversion of continuous to binary</HEADING>
<P>Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or PANSS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>), this could be considered as a clinically significant response (<LINK REF="REF-Leucht-2005" TYPE="REFERENCE">Leucht 2005</LINK>; <LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>). If data based on these thresholds were not available, we used the primary cut-off presented by the original authors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.7 Direction of graphs</HEADING>
<P>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for dance therapy. If we had to report data where the left of the line indicates an unfavourable outcome, this was noted in the relevant graphs.</P>
</SUBSECTION>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-10-02 15:15:56 +0100" MODIFIED_BY="[Empty name]">
<P>For this update, JR and JX worked independently using criteria described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) to assess trial quality. This new set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting.</P>
<P>Where inadequate details of randomisation and other characteristics of the included trial were provided, we contacted the authors of the study in order to obtain additional information.</P>
<P>We have noted the level of risk of bias in both the text of the review and in the <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-10-02 15:15:57 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Binary data</HEADING>
<P>For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). The Number Needed to Treat/Harm (NNT/H) statistic with its confidence intervals is intuitively attractive to clinicians but is problematic both in its accurate calculation in meta-analyses and interpretation (<LINK REF="REF-Hutton-2009" TYPE="REFERENCE">Hutton 2009</LINK>). For binary data presented in the 'Summary of findings' table, where possible, we calculated illustrative comparative risks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Continuous data</HEADING>
<P>For continuous outcomes we estimated mean difference (MD) between groups. We would prefer not to calculate effect size measures (standardised mean difference (SMD)). However, if scales of very considerable similarity had been used, we would have presumed there was a small difference in measurement, and we would have calculated effect size and transformed the effect back to the units of one or more of the specific instruments.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-10-02 15:21:06 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Cluster trials</HEADING>
<P>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice), but analysis and pooling of clustered data poses problems. Authors often fail to account for intra-class correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby P values are spuriously low, confidence intervals (CIs) unduly narrow and statistical significance overestimated. This causes type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>; <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>If clustering had not been accounted for in primary studies, we planned to present data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review, if we include cluster randomised trials, we will seek to contact first authors of such studies to obtain intra-class correlation coefficients (ICCs) for their clustered data and to adjust for this by using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering has been incorporated into the analysis of primary studies, we will present these data as if from a non-cluster randomised study, but adjust for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICC [Design effect = 1+(m-1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC is not reported it will be assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>If cluster studies have been appropriately analysed taking into account ICCs and relevant data documented in the report, synthesis with other studies would be possible using the generic inverse variance technique.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Cross-over trials</HEADING>
<P>A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a wash-out phase. For the same reason cross-over trials are not appropriate if the condition of interest is unstable (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). As both effects are very likely in severe mental illness, if we had included cross-over trials, we intended only to use the data of the first phase of cross-over studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Studies with multiple treatment groups</HEADING>
<P>No studies with multiple treatment groups were included. </P>
<P>In future updates of this review, if an included study involves more than two treatment arms, if relevant, we will present the additional treatment arms in comparisons. If data are binary, we will simply add and combine them within the two-by-two table. If data are continuous, we will combine data following the formula in section 7.7.3.8 (Combining groups) of the <I>Cochrane Handbook for Systemic reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Where the additional treatment arms are not relevant, we will not reproduce these data.</P>
<P/>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-10-02 15:15:57 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Overall loss of credibility</HEADING>
<P>At some degree of loss of follow-up, data must lose credibility (<LINK REF="REF-Xia-2009" TYPE="REFERENCE">Xia 2009</LINK>). We chose that, for any particular outcome, should more than 40% of data be unaccounted for, we would not reproduce these data or use them within analyses. If, however, more than 40% of those in one arm of a study were lost, but the total loss was less than 40%, we addressed this within the 'Summary of findings' table by down-rating quality. Finally, we also downgraded quality within the 'Summary of findings' table for losses of 25% to 40% in total.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Binary</HEADING>
<P>In the case where attrition for a binary outcome was between 0% and 40% and where these data were not clearly described, we presented data on a 'once-randomised-always-analyse' basis (an intention-to-treat analysis). Those leaving the study early were all assumed to have the same rates of negative outcome as those who completed, with the exception of the outcome of death and adverse effects. For these outcomes the rate of those who stayed in the study - in that particular arm of the trial - were used for those who did not. We undertook a sensitivity analysis to test how prone the primary outcomes were to change when 'completer' data only were compared to the intention-to-treat analysis using the above assumptions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Continuous</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Attrition</HEADING>
<P>In the case where attrition for a continuous outcome is between 0% and 40% and completer-only data were reported, we reproduced these.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Standard deviations</HEADING>
<P>If standard deviations (SDs) were not reported, we first tried to obtain the missing values from the authors. If not available, where there were missing measures of variance for continuous data, but an exact standard error (SE) and confidence intervals (CIs) available for group means, and either the P value or T value available for differences in mean, we can calculate them according to the rules described in the <I>Handbook</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>): When only the SE is reported, SDs are calculated by the formula SD = SE * square root (n). Chapters 7.7.3 and 16.1.3 of the <I>Handbook</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) present detailed formulae for estimating SDs from P values, T or F values, CIs, ranges or other statistics. If these formulae do not apply, we can calculate the SDs according to a validated imputation method which is based on the SDs of the other included studies (<LINK REF="REF-Furukawa-2006" TYPE="REFERENCE">Furukawa 2006</LINK>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study&#8217;s outcome and thus to lose information. We nevertheless examined the validity of the imputations in a sensitivity analysis excluding imputed values.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3 Last observation carried forward</HEADING>
<P>We anticipated that in some studies the method of last observation carried forward (LOCF) would be employed within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (<LINK REF="REF-Leucht-2007" TYPE="REFERENCE">Leucht 2007</LINK>). If LOCF data had been used in the trial and less than 40% of the data had been assumed, we planned to reproduce these data and indicate that they were the product of LOCF assumptions.</P>
</SUBSECTION>
</SUBSECTION>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-10-02 15:15:57 +0100" MODIFIED_BY="Lelia Duley">
<P>We only included one study in this version of the review. In future updates of this review, if we include more studies, we will use the following methods to assess heterogeneity.</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Clinical heterogeneity</HEADING>
<P>We will consider all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We will simply inspect all studies for clearly outlying people or situations which we had not predicted would arise. When such situations or participant groups arise, we will discuss these fully.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Methodological heterogeneity</HEADING>
<P>We will consider all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We will simply inspect all studies for clearly outlying methods which we had not predicted would arise. When such methodological outliers arise, we will discuss these fully.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Statistical heterogeneity</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Visual inspection</HEADING>
<P>We will visually inspect graphs to investigate the possibility of statistical heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Employing the I<SUP>2</SUP> statistic</HEADING>
<P>We will investigate heterogeneity between studies by considering the I<SUP>2 </SUP>method alongside the Chi<SUP>2</SUP> P value. The I<SUP>2 </SUP>provides an estimate of the percentage of inconsistency thought to be due to chance (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). The importance of the observed value of I<SUP>2 </SUP>depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. P value from Chi<SUP>2</SUP> test, or a confidence interval for I<SUP>2</SUP>). An I<SUP>2 </SUP>estimate greater than or equal to around 50% accompanied by a statistically significant Chi<SUP>2</SUP> statistic will be interpreted as evidence of substantial levels of heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). If substantial levels of heterogeneity are found in the primary outcome, we will explore reasons for the heterogeneity (<LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-10-02 15:15:57 +0100" MODIFIED_BY="Lelia Duley">
<P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). These are described in Section 10 of the <I>Handbook</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small-study effects. We were unable to use funnel plots for outcomes as there was only one included study. In future updates of this review, we will not use funnel plots for outcomes where there are 10 or fewer studies, or where all studies are of similar sizes. In other cases, where funnel plots are possible, we will seek statistical advice in their interpretation.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-10-02 15:15:57 +0100" MODIFIED_BY="[Empty name]">
<P>We understand that there is no closed argument for preference for use of fixed-effect or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random-effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random-effects model: it puts added weight onto small studies which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. In this version of the review we were unable to combine data. In future updates, if there are more trials, we will use the fixed-effect model for all analyses. The reader will, however, able to choose to inspect the data using the random-effects model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-10-02 15:15:57 +0100" MODIFIED_BY="Lelia Duley">
<SUBSECTION>
<HEADING LEVEL="4">1. Subgroup analyses - only primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.1 Clinical state, stage or problem</HEADING>
<P>We proposed to undertake this review and provide an overview of the effects of dance therapy for people with schizophrenia in general. In addition, however, we tried to report data on subgroups of people in the same clinical state, stage and with similar problems.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Investigation of heterogeneity</HEADING>
<P>There is only one included study.</P>
<P>In future updates, if we include more studies, if inconsistency is high, we will report this. First, we will investigate whether data had been entered correctly. Second, if data are correct, we will visually inspect the graph and successively remove outlyingstudies to see if homogeneity is restored. For this review, we have decided that should this occur with data contributing to the summary finding of no more than around 10% of the total weighting, we will present data. If not, then we will not pool data and we will discuss these issues. We know of no supporting research for this 10% cut-off, but we use prediction intervals as an alternative to this unsatisfactory state.</P>
<P>When unanticipated clinical or methodological heterogeneity is obvious we will simply state hypotheses regarding these for future reviews or versions of this review. We do not anticipate undertaking analyses relating to these.</P>
</SUBSECTION>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-10-02 15:15:57 +0100" MODIFIED_BY="[Empty name]">
<P>We would have applied all sensitivity analyses to the primary outcomes of this review.</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Implication of randomisation</HEADING>
<P>We aimed to include trials in a sensitivity analysis if they were described in some way so as to imply randomisation. For the primary outcomes, we would have included these studies and if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, then we would have entered all data from these studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Assumptions for lost binary data</HEADING>
<P>Where assumptions had to be made regarding people lost to follow-up (see <LINK TAG="MISSING_DATA" TYPE="SECTION">Dealing with missing data</LINK>), we compared the findings of the primary outcomes when we use our assumption/s and when we used data only from people who completed the study to that point. If there was a substantial difference, we reported results and discussed them but continued to employ our assumption.</P>
<P>If assumptions had to be made regarding missing SDs data (see <LINK TAG="MISSING_DATA" TYPE="SECTION">Dealing with missing data</LINK>), we planned to compare the findings of the primary outcomes when we used our assumption/s and when we used data only from people who completed the study to that point. A sensitivity analysis would have been undertaken to test how prone results were to change when completer-only data only were compared to the imputed data using the above assumption. If there had been a substantial difference, we would have reported results and discussed them but we would have continued to employ our assumption</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Risk of bias</HEADING>
<P>We planned to analyse the effects of excluding trials that were judged to be at high risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available): allocation concealment, blinding and outcome reporting for the meta-analysis of the primary outcome. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, then we would have included data from these trials in the analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Imputed values</HEADING>
<P>We also intended to undertake a sensitivity analysis to assess the effects of including data from trials if we used imputed values for ICC in calculating the design effect in cluster randomised trials.</P>
<P>If we had noted substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we would not have pooled data from the excluded trials with the other trials contributing to the outcome, but presented them separately.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Fixed-effect and random-effects</HEADING>
<P>We used a fixed-effect model to calculate data from the one included study.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-10-02 15:15:57 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-10-02 15:15:57 +0100" MODIFIED_BY="[Empty name]">
<P>For more detailed description of each studies, please refer to the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> tables.<BR/>
</P>
<SEARCH_RESULTS MODIFIED="2013-10-02 15:15:57 +0100" MODIFIED_BY="Lelia Duley">
<SUBSECTION>
<HEADING LEVEL="4">1. 2007 search</HEADING>
<P>We found six studies in the 2007 search. After obtaining the full articles, five were excluded, leaving only one possible to include. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. 2012 search</HEADING>
<P>We identified 1020 citations (1019 from the main Chinese database and one from the Cochrane Schizophrenia Group Trials register) from the initial search strategy.</P>
<P>In total, 1026 citations (six from 2007 search and 1020 from 2012 search) were screened. After removing duplicate and irrelevant references, 12 references were considered as potentially relevant and they were retrieved for further assessment; 11 were excluded (four not randomised, four not dance therapy, two no usable data, one an ongoing study, <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>), leaving only one to include in this review. Please also see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
</SUBSECTION>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-10-02 15:15:57 +0100" MODIFIED_BY="[Empty name]">
<P>No new trials were added from the new search in 2012.</P>
<P>One study, <LINK REF="STD-Rohricht-2006" TYPE="STUDY">Rohricht 2006</LINK> is included in this review. This randomised, single blind study used sealed envelopes to conceal allocation.</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Length of trial</HEADING>
<P>The treatment period of <LINK REF="STD-Rohricht-2006" TYPE="STUDY">Rohricht 2006</LINK> lasted for 10 weeks with a follow-up four months.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Participants</HEADING>
<P>All participants were diagnosed with schizophrenia (Diagnostic Statistical Manual, version 4 (DSM-IV)). Participants were adult male and female out-patients between 20 to 55 years of age. People with organic brain disease, severe/chronic physical illness or substance misuse were excluded.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Setting</HEADING>
<P>This trial took place in the community.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Study size</HEADING>
<P>Study size was small with only 45 people randomised.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Intervention</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">5.1 Intervention group</HEADING>
<P>All participants in the intervention group maintained their standard care and in addition received dance therapy. The dance therapy used had five stages: a) opening circle, to describe feelings and energy level; b) warm-up section, standing in a circle and warm-up using different body parts and movements; c) structured task section, mirroring each other's movement, creating body image sculpture in partners; d) creative movement section, group mirroring, creating group sculptures. reflecting on how this feels; e) closing circle, reflecting on group experience, re-focusing on self with body-oriented exercises such as self-touch, verbal integration.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.2 Control group</HEADING>
<P>The control group received standard care plus supportive counselling. For the supportive counselling, the therapist facilitated a safe and supportive atmosphere and gave the participants opportunity to talk about specific difficulties. The group then engaged in discussing their experience and trying to identify the contributing factors to the problems.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Outcomes</HEADING>
<P>A number of outcomes were reported. Positive and Negative Syndrome Scale (PANSS) negative, positive and total scores were measured at the end of treatment and at four-month follow-up. We were, however, unable to use assessment data at the four-month follow-up, as over 40% of the participants were lost to follow-up at this stage. Participant satisfaction with treatment was reported using Client's Assessment of Treatment Scale (CAT) and Manchester Short Assessment of Quality of Life (MANSA) scales. Leaving the study early and losses to follow-up were also reported. Extrapyramidal symptom scale scores were reported. These data were skewed (please refer to 'other data' table). However, the service utilisation and relapse data were not reported in the included study.</P>
<P>
<B>6.1 Mental state</B>
</P>
<P>Positive and Negative Syndrome Scale - PANSS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>)</P>
<P>This schizophrenia scale has 30 items, each of which can be defined on a seven-point scoring system varying from one (absent) to seven (extreme). This scale can be divided into three sub-scales for measuring the severity of general psychopathology, positive symptoms, and negative symptoms. A low score indicates lesser severity.</P>
<SUBSECTION>
<HEADING LEVEL="5">6.2 Satisfaction with care</HEADING>
<P>Client's Assessment of Treatment Scale - CAT (<LINK REF="REF-Priebe-1995" TYPE="REFERENCE">Priebe 1995</LINK>)<BR/>This is a Likert scale that measures seven aspects of treatment. Each aspect was rated on an 11-point rating scale ranging form zero (extreme negative) to 10 (extreme positive). High score equals positive outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.3 Adverse effects (skewed data)</HEADING>
<P>Extrapyramidal Symptom Scale - EPS (<LINK REF="REF-Simpson-1970" TYPE="REFERENCE">Simpson 1970</LINK>)<BR/>This 10-item scale, with a scoring system of zero to four for each item, measures drug-induced Parkinsonism, a short-term drug-induced movement disorder. A low score indicates low levels of Parkinsonism.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.4 Quality of life</HEADING>
<P>Manchester Short Assessment of Quality of Life - MANSA (<LINK REF="REF-Priebe-1999" TYPE="REFERENCE">Priebe 1999</LINK>)<BR/>A 16-item scale (four objective, 12 subjective questions), measures satisfaction with life, job, financial situation, number and quality of friends, leisure activities, accommodation, personal safety, sex life, relationship with family, physical and mental health etc. Each item is rated on a seven-point scale, from one (could not be worse) to seven (could not be better). Higher score indicates a better quality of life.</P>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-10-02 15:15:57 +0100" MODIFIED_BY="[Empty name]">
<P>For more detailed description of each study, please refer to the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
<P>We have now excluded 11 studies from this review, six of which we excluded after the 2012 search (<LINK REF="STD-Qu-2007" TYPE="STUDY">Qu 2007</LINK>; <LINK REF="STD-Tan-2010" TYPE="STUDY">Tan 2010</LINK>; <LINK REF="STD-Tang-2011" TYPE="STUDY">Tang 2011</LINK>; <LINK REF="STD-Yao-2008" TYPE="STUDY">Yao 2008</LINK>; <LINK REF="STD-Zhou-2009" TYPE="STUDY">Zhou 2009</LINK>; <LINK REF="STD-ISRCTN-2012" TYPE="STUDY">ISRCTN 2012</LINK>), and five of which we excluded after the 2007 search (<LINK REF="STD-Apter-1978" TYPE="STUDY">Apter 1978</LINK>; <LINK REF="STD-Killaspy-1997" TYPE="STUDY">Killaspy 1997</LINK>; <LINK REF="STD-Su-1999" TYPE="STUDY">Su 1999</LINK>; <LINK REF="STD-Wu-2003" TYPE="STUDY">Wu 2003</LINK>; <LINK REF="STD-Yang-2005" TYPE="STUDY">Yang 2005</LINK>). Four of the excluded studies were not randomised (<LINK REF="STD-Tang-2011" TYPE="STUDY">Tang 2011</LINK>; <LINK REF="STD-Wu-2003" TYPE="STUDY">Wu 2003</LINK>; <LINK REF="STD-Yao-2008" TYPE="STUDY">Yao 2008</LINK>; <LINK REF="STD-Zhou-2009" TYPE="STUDY">Zhou 2009</LINK>).Two trials have no useable data (<LINK REF="STD-Apter-1978" TYPE="STUDY">Apter 1978</LINK>; <LINK REF="STD-Su-1999" TYPE="STUDY">Su 1999</LINK>). All data were reported and there are no mean or variances reported. <LINK REF="STD-Killaspy-1997" TYPE="STUDY">Killaspy 1997</LINK>, <LINK REF="STD-Yang-2005" TYPE="STUDY">Yang 2005</LINK>, <LINK REF="STD-Qu-2007" TYPE="STUDY">Qu 2007</LINK> and <LINK REF="STD-Tan-2010" TYPE="STUDY">Tan 2010</LINK> were randomised trials but their interventions were not dance therapy (art therapy, group psychoeducation and music therapy plus dance therapy). One study was ongoing(<LINK REF="STD-ISRCTN-2012" TYPE="STUDY">ISRCTN 2012</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Studies awaiting assessment</HEADING>
<P>No studies are awaiting assessment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ongoing studies</HEADING>
<P>We are aware of one ongoing study (See <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>).</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-10-02 15:15:57 +0100" MODIFIED_BY="[Empty name]">
<P>For summary of risk of bias across included studies please see <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> and <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>.<BR/>
</P>
<ALLOCATION MODIFIED="2008-11-12 13:30:07 +0000" MODIFIED_BY="[Empty name]">
<P>Although <LINK REF="STD-Rohricht-2006" TYPE="STUDY">Rohricht 2006</LINK> did not fully describe how they randomised participants, they did state sealed envelopes were used for allocation concealment.</P>
</ALLOCATION>
<BLINDING MODIFIED="2008-11-07 16:45:08 +0000" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Rohricht-2006" TYPE="STUDY">Rohricht 2006</LINK> was single blind (assessor blind).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-02-06 07:19:05 +0000" MODIFIED_BY="[Empty name]">
<P>Loss to follow-up was high in the control group with over 40% loss to follow-up. We are not sure if people would have left each group for different reasons. The study does not reassure us on this point.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2008-10-23 15:33:55 +0100" MODIFIED_BY="[Empty name]">
<P>There is no selective reporting. All measurements as stated in the 'methods' section of the paper are reported. </P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-10-02 15:15:57 +0100" MODIFIED_BY="Lelia Duley">
<P>For <LINK REF="STD-Rohricht-2006" TYPE="STUDY">Rohricht 2006</LINK>, data reporting was good. It would have helped to have more detail on why people left early.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-10-02 15:15:57 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Primary outcome</HEADING>
<P>The only included study did not report the outcomes about service utilisation and relapse and no data were provided for them.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Secondary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Mental state</HEADING>
<P>Short-term mental state data from the PANSS were presented.</P>
<SUBSECTION>
<HEADING LEVEL="6">2.1.1 Total scores</HEADING>
<P>The average total endpoint scores were equivocal (1 randomised controlled trial (RCT), n = 43, mean difference (MD) -0.50 95% confidence interval (CI) -11.80 to 10.80)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2.1.2 Positive symptoms</HEADING>
<P>Again, no significant differences in positive scores were found between groups (1 RCT, n = 43, MD 2.50 95% CI -0.67 to 5.67).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2.1.3 Negative symptoms</HEADING>
<P>Here significant differences, favouring dance therapy were found. Those in the dance therapy group had significantly lower average endpoint scores (1 RCT, n = 43, MD -4.40 95% CI -8.15 to -0.65) and the numbers with a greater than 20% reduction in score were also just significantly higher in the dance therapy group (1 RCT, n = 45, risk ratio (RR) 0.62 95% CI 0.39 to 0.97).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Clinical global response-leaving the study early</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">2.2.1 Short term</HEADING>
<P>At the end of treatment there was no significant difference between groups in the number of people leaving the study early (1 RCT, n = 45, RR 0.44 95% CI 0.04 to 4.49).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2.2.2 Long term</HEADING>
<P>Again, at the four-month follow-up, there was no significant difference between groups in the number of people leaving the study early (1 RCT, n = 45, RR 0.68 95% CI 0.31 to 1.51).</P>
<P>
<B>2.3. Satisfaction with care</B>
</P>
<P>The CAT scale was used to present short-term data for satisfaction with care. At the end of therapy there was no significant difference in effect between groups (1 RCT, n = 42, MD 0.40 95% CI -0.78 to 1.58)</P>
<P>
<B>2.4. Quality of life</B>
</P>
<P>Short-term data from the MANSA scale were presented and again, at the end of therapy in this trial, there were no significant differences in quality of life between groups (1 RCT, n = 39, MD 0.00 95% CI -0.48 to 0.48). </P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-10-02 15:22:40 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2013-10-02 15:22:40 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">COMPARISON: DANCE THERAPY versus STANDARD CARE</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Service utilisation</HEADING>
<P>It is unfortunate that no data are available for service utilisation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Clinical global response</HEADING>
<P>There was a higher attrition rate in the control group than the experimental group. However, we did not find a significant difference between groups in the number of people leaving the study early at the end of treatment and at the four-month follow-up. The better adherence of patients to body-oriented psychological therapy (BPT) shows a relatively good acceptance of the experimental treatment, which may be considered as a positive effect of BPT itself and facilitate its use in practice. No data on relapse were reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Mental state</HEADING>
<P>Pooled data found a significant difference between treatment groups on the PANSS endpoint negative score and PANSS negative symptoms reduction. At the end of treatment, significantly more people in the dance therapy group had a greater than 20% reduction in PANSS negative symptom score (1 RCT, n = 45, RR 0.62 CI 0.39 to 0.97), and overall, average negative endpoint scores were lower (1 RCT, n = 43, MD -4.40 CI -8.15 to -0.65). It is hard to gauge what these data mean in everyday life. A 20% reduction may not be that important to some people; a difference in score of four points may be negligible to many. At the same time, a 20% reduction in PANSS negative symptom score just where it is needed for others may be a considerable improvement. This remains one small trial with one interesting result.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Satisfaction with treatment</HEADING>
<P>Patients' assessment of treatment was broadly positive: the mean CAT score did not differ between groups after treatment. Equally, patients' ratings of the therapeutic relationship was generally appreciative and did not differ between groups after treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Quality of life</HEADING>
<P>Limited data from this one included study found no significant difference between groups after treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Adverse effects</HEADING>
<P>Adverse effects were reported using the extrapyramidal symptoms (EPS) scale scores but data from this scale were skewed. The only one included study found than dosages of antipsychotic medication as well as EPS scores did not differ significant between the two groups.</P>
</SUBSECTION>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-01-29 12:45:51 +0000" MODIFIED_BY="Lelia Duley">
<SUBSECTION>
<HEADING LEVEL="4">1. Completeness</HEADING>
<P>Evidence from the included study is certainly relevant to the review question, but it is not sufficient to address all of the objectives of this review. We do not really have any good data on service utilisation or other crude but useful outcomes such as global response.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Applicability</HEADING>
<P>As stated in the paper, "A single therapist administered [the therapy], and it remains unclear whether the effect can be replicated across different therapists and in other samples and settings" (<LINK REF="STD-Rohricht-2006" TYPE="STUDY">Rohricht 2006</LINK>).</P>
</SUBSECTION>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-10-02 15:15:57 +0100" MODIFIED_BY="[Empty name]">
<P>Overall, evidence in this review is weak, as we were only able to include one small trial but the quality of this trial is good (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). Randomisation was undertaken by a project co-ordinator, who had no involvement in data collection and assessment, opening a sealed envelope. Allocation concealment and single blind assessment were used to ensure the quality of outcomes.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-10-02 15:15:57 +0100" MODIFIED_BY="[Empty name]">
<P>The process of searching for studies was thorough. We followed strictly the review protocol in the process of study selection, data extraction and analysis. However, usable data from two studies (<LINK REF="STD-Apter-1978" TYPE="STUDY">Apter 1978</LINK>; <LINK REF="STD-Su-1999" TYPE="STUDY">Su 1999</LINK>) could not be obtained, which led to the exclusion of potentially valuable data. Review author JX contacted the authors of these two papers for unpublished data in 2007, but has not received any reply to date. Exclusion of these data could increase the likelihood of bias. In this update, we could detect no other source of bias such as biased source of funding to authors.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2008-11-11 15:40:20 +0000" MODIFIED_BY="Lelia Duley">
<P>As far as we are aware, this is the only systematic review on dance therapy for schizophrenia.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-10-02 15:15:57 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-10-02 15:15:57 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. For those with schizophrenia</HEADING>
<P>The data in this review are inconclusive. There is no evidence to support - or refute - the use of dance therapy. Those with schizophrenia may wish to be involved in future research to help to resolve this lack of evidence.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. For clinicians</HEADING>
<P>Based on evidence in the current review, there is no reason for clinicians to either encourage or discourage the use of dance therapy. More future research is needed in order to reach a conclusion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. For policy makers/managers</HEADING>
<P>Until there are more data, there is no evidence in this review to support change in policy.</P>
</SUBSECTION>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-10-02 15:15:57 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. General</HEADING>
<P>Two trials were excluded from this review, due to the poor quality of data reporting, diminishing the already small evidence-base (<LINK REF="STD-Apter-1978" TYPE="STUDY">Apter 1978</LINK>; <LINK REF="STD-Su-1999" TYPE="STUDY">Su 1999</LINK>). Following <A HREF="http://www.consort-statement.org/">CONSORT</A> guidance more closely would have made data from <LINK REF="STD-Rohricht-2006" TYPE="STUDY">Rohricht 2006</LINK> more valuable and may have helped considerably increased the power of this review by allowing us to include <LINK REF="STD-Apter-1978" TYPE="STUDY">Apter 1978</LINK> and <LINK REF="STD-Su-1999" TYPE="STUDY">Su 1999</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Specific</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Reviews</HEADING>
<P>Excluded studies, nearly meeting the inclusion criteria for this review suggest updates or new reviews are indicated to keep the broader area of 'arts' therapies for schizophrenia complete (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Trials</HEADING>
<P>Larger trials with simple, straight forward design should be encouraged for future research. Clear description of randomisation, allocation concealment and blinding would have reassured us that bias had been minimised. Reporting of more clinically meaningful outcomes such as relapse, admission to hospital, quality of life, cost of care, satisfaction with care, leaving the study early should be encouraged. Continuous data should be reported with mean, standard deviations and number of participants. Endpoint score should always be used when reporting data derived from scales. We have not the experience, nor have we invested the effort of thought or commitment of those who have undertaken trials in this difficult area. There are, however, some gains from producing an overview in this way and we suggest an outline design for future trials (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-10-02 15:24:36 +0100" MODIFIED_BY="[Empty name]">
<P>The authors would like to thank Judy Wright for running the trials search and Clive Adams for editorial input and Chunbo Li for his help in the preparation of this updating manuscript and editing.</P>
<P>We would also like to acknowledge and thank our consumer contributors, Janey Antoniou and Ben Gray of RETHINK, UK <A HREF="http://www.rethink.org">www.rethink.org</A>, who have written Plain language summaries (PLS) of this review, Jane wrote the original PLS and Ben has written the current version for this update.</P>
<P>Samantha Roberts, the Trials Search Co-ordinator of the Cochrane Schizophrenia Group ran the 2012 search.</P>
<P>Finally, we would like to acknowledge Tessa Grant for her help in trial selection for the previous version of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-10-02 15:15:58 +0100" MODIFIED_BY="[Empty name]">
<P>Juanjuan Ren - no known conflict for interest.</P>
<P>Jun Xia - no known conflict of interest.</P>
<P>Tessa Grant - no known conflict of interest (2009 version of the review).</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-05-23 14:29:09 +0100" MODIFIED_BY="[Empty name]">
<P>JR - study selection, data extraction, input and analysis, writing up the review in 2012 update.</P>
<P>JX - developing the protocol, study selection, data extraction, input and analysis, writing up the review in previous version.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2008-11-10 11:39:41 +0000" MODIFIED_BY="[Empty name]">
<P>There are no differences between protocol and review.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-10-02 15:29:13 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-10-02 15:26:48 +0100" MODIFIED_BY="Lelia Duley">
<INCLUDED_STUDIES MODIFIED="2008-04-29 21:32:32 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Rohricht-2006" MODIFIED="2008-04-27 16:56:44 +0100" MODIFIED_BY="[Empty name]" NAME="Rohricht 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-04-27 16:56:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rohricht F, Priebe S</AU>
<TI>Effect of body-oriented psychological therapy on negative symptoms in schizophrenia: a randomized controlled trial</TI>
<SO>Psychological Medicine</SO>
<YR>2006</YR>
<VL>36</VL>
<NO>5</NO>
<PG>669-78</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="EMBASE" VALUE="171807"/>
<IDENTIFIER TYPE="MEDLINE" VALUE="16608559"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-10-02 15:26:48 +0100" MODIFIED_BY="Lelia Duley">
<STUDY DATA_SOURCE="PUB" ID="STD-Apter-1978" MODIFIED="2013-09-23 15:51:03 +0100" MODIFIED_BY="[Empty name]" NAME="Apter 1978" YEAR="1978">
<REFERENCE MODIFIED="2013-06-19 03:48:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Apter A, Sharir I, Tyano S, Wijsenbeek H</AU>
<TI>Movement therapy with psychotic adolescents</TI>
<SO>British Journal of Medical Psychology</SO>
<YR>1978</YR>
<VL>51</VL>
<NO>2</NO>
<PG>155-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-ISRCTN-2012a" MODIFIED="2013-07-17 16:34:03 +0100" MODIFIED_BY="[Empty name]" NAME="ISRCTN 2012a" YEAR="2012">
<REFERENCE MODIFIED="2013-07-17 16:34:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>Effectiveness and cost-effectiveness of body psychotherapy in the treatment of negative symptoms of schizophrenia</TI>
<SO>http://www.controlled-trials.com/ISRCTN84216587</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS>
<IDENTIFIER TYPE="ISRCTN" VALUE="84216587"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Killaspy-1997" MODIFIED="2008-11-11 15:28:17 +0000" MODIFIED_BY="Lelia Duley" NAME="Killaspy 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-11-11 15:28:17 +0000" MODIFIED_BY="Lelia Duley" PRIMARY="NO" TYPE="OTHER">
<AU>Killaspy H</AU>
<TI>Interactive group art therapy as an adjunctive treatment for people with schizophrenia</TI>
<SO>National Research Register</SO>
<YR>1997</YR>
<IDENTIFIERS MODIFIED="2008-11-11 15:28:17 +0000" MODIFIED_BY="Lelia Duley">
<IDENTIFIER TYPE="OTHER" VALUE="ISRCTN46150447"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qu-2007" MODIFIED="2013-10-02 15:25:53 +0100" MODIFIED_BY="[Empty name]" NAME="Qu 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-10-02 15:25:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qu Y, Xiao G, Ma Y</AU>
<TI>Effect of congnitive remediation therapy on improving clinical symtoms and social functions in patients with chronic schizophrenia</TI>
<TO>&#35748;&#30693;&#30699;&#27491;&#27835;&#30103;&#23545;&#24930;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#20020;&#24202;&#30151;&#29366;&#21644;&#31038;&#20250;&#21151;&#33021;&#30340;&#24433;&#21709;</TO>
<SO>Journal of Clinical Rehabilitative Tissue Engineering Research</SO>
<YR>2007</YR>
<VL>11</VL>
<NO>52</NO>
<PG>10553-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-01-14 07:17:41 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Su-1999" MODIFIED="2013-09-23 15:51:21 +0100" MODIFIED_BY="[Empty name]" NAME="Su 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-09-23 10:15:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Su L,Fan Z, Qu Y</AU>
<TI>The effect of dance therapy for chronic schizophrenic patients
</TI>
<SO>Chinese Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>32</VL>
<NO>3</NO>
<PG>167-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="MEDI19911"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tan-2010" MODIFIED="2013-10-02 15:26:08 +0100" MODIFIED_BY="[Empty name]" NAME="Tan 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-10-02 15:26:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tan S, Zhou Y, Wang J</AU>
<TI>Effect of cognitive remediation therapy and computerized congnitive remediation therapy on cognitive defiicits in patients with schizophrenia: a randomized controlled study</TI>
<SO>Chinese Journal of Psychiatry</SO>
<YR>2010</YR>
<VL>43</VL>
<NO>3</NO>
<PG>140-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tang-2011" MODIFIED="2013-10-02 15:26:15 +0100" MODIFIED_BY="[Empty name]" NAME="Tang 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-10-02 15:26:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tang Z, Peng L, Tian F</AU>
<TI>The clinical observation of dance therapy for chronic schizophrenia</TI>
<TO>&#33310;&#36424;&#30103;&#27861;&#23545;&#24930;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#20020;&#24202;&#35266;&#23519;</TO>
<SO>Sichun Mental Health</SO>
<YR>2011</YR>
<VL>24</VL>
<NO>3</NO>
<PG>182-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2003" MODIFIED="2012-09-18 04:35:22 +0100" MODIFIED_BY="Lelia Duley" NAME="Wu 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-11 15:28:43 +0000" MODIFIED_BY="Lelia Duley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu Y, Zhao F</AU>
<TI>Effect of music and dance on recovery of schizophrenia</TI>
<SO>Health Psychology Journal</SO>
<YR>2003</YR>
<VL>11</VL>
<NO>3</NO>
<PG>207-8</PG>
<IDENTIFIERS MODIFIED="2008-11-11 15:28:43 +0000" MODIFIED_BY="Lelia Duley">
<IDENTIFIER TYPE="OTHER" VALUE="MEDI0308"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2005" MODIFIED="2012-09-21 03:23:21 +0100" MODIFIED_BY="Lelia Duley" NAME="Yang 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-09-21 03:22:58 +0100" MODIFIED_BY="Lelia Duley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang R, Lv H, Lou F</AU>
<TI>The rehabilitation effect of group psychotherapy on chronic schizophrenic patient</TI>
<SO>Occupation and Health</SO>
<YR>2005</YR>
<VL>21</VL>
<NO>6</NO>
<PG>936</PG>
<IDENTIFIERS MODIFIED="2012-09-21 03:22:33 +0100" MODIFIED_BY="Lelia Duley">
<IDENTIFIER MODIFIED="2012-09-21 03:22:33 +0100" MODIFIED_BY="[Empty name]" OTHERTYPE="CAJ" TYPE="OTHER" VALUE="MEDI0507S1"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yao-2008" MODIFIED="2013-10-02 15:26:33 +0100" MODIFIED_BY="[Empty name]" NAME="Yao 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-10-02 15:26:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yao Y</AU>
<TI>Rehabilitation of music and dance therapy for patients with schizophrenia</TI>
<TO>&#38899;&#20048;&#33310;&#36424;&#27835;&#30103;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#30340;&#24247;&#22797;&#20316;&#29992;</TO>
<SO>Chinese Medicine Research and Clinical</SO>
<YR>2008</YR>
<VL>6</VL>
<NO>2</NO>
<PG>13-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2009" MODIFIED="2013-10-02 15:26:48 +0100" MODIFIED_BY="[Empty name]" NAME="Zhou 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-10-02 15:26:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou C, Dai F, Pan D</AU>
<TI>Act on of dance therapy improved the maladjustment in hospital patient with psychosis</TI>
<TO>&#33310;&#36424;&#30103;&#27861;&#23545;&#25913;&#21892;&#20303;&#38498;&#31934;&#31070;&#30149;&#24739;&#32773;&#36866;&#24212;&#19981;&#33391;&#30340;&#20316;&#29992;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health</SO>
<YR>2009</YR>
<VL>21</VL>
<NO>23</NO>
<PG>3048-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-06-19 03:48:09 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2012-08-07 07:44:32 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-ISRCTN-2012" MODIFIED="2012-08-07 07:44:32 +0100" MODIFIED_BY="[Empty name]" NAME="ISRCTN 2012" YEAR="2012">
<IDENTIFIERS MODIFIED="2012-08-07 07:44:21 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-07 07:44:21 +0100" MODIFIED_BY="[Empty name]" TYPE="ISRCTN" VALUE="84216587"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-10-02 15:29:13 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-10-02 15:28:51 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1996" MODIFIED="2008-11-11 16:08:18 +0000" MODIFIED_BY="Lelia Duley" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="FI020600"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" MODIFIED="2008-11-11 16:08:18 +0000" MODIFIED_BY="Lelia Duley" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" MODIFIED="2012-07-18 12:25:45 +0100" MODIFIED_BY="[Empty name]" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al</AU>
<TI>The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use</TI>
<TO>Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite</TO>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>405-11</PG>
<IDENTIFIERS MODIFIED="2012-07-18 12:25:43 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="10667106"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chodorow-1991" MODIFIED="2013-10-02 15:27:07 +0100" MODIFIED_BY="Lelia Duley" NAME="Chodorow 1991" TYPE="BOOK">
<AU>Chodorow J</AU>
<SO>Dance Therapy and Depth Psychology: the Moving Imagination</SO>
<YR>1991</YR>
<PB>Routledge</PB>
<CY>London</CY>
<IDENTIFIERS MODIFIED="2008-11-11 16:44:21 +0000" MODIFIED_BY="Lelia Duley">
<IDENTIFIER MODIFIED="2008-11-11 16:44:21 +0000" MODIFIED_BY="Lelia Duley" TYPE="OTHER" VALUE="ISBN 0-415-05301-3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" MODIFIED="2012-07-18 12:25:45 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection for meta-analyses of binary data</TI>
<SO>Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town</SO>
<YR>2000</YR>
<PB>The Cochrane Collaboration</PB>
<CY>Cape Town</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" MODIFIED="2008-11-11 16:08:18 +0000" MODIFIED_BY="Lelia Duley" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazier LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>6</NO>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" MODIFIED="2008-11-11 16:08:18 +0000" MODIFIED_BY="Lelia Duley" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2008-11-11 16:08:18 +0000" MODIFIED_BY="Lelia Duley" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey-Smith G, Schneider M, Minder CSO</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>13</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2012-07-18 12:25:45 +0100" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Espenak-1981" MODIFIED="2013-10-02 15:27:19 +0100" MODIFIED_BY="Lelia Duley" NAME="Espenak 1981" TYPE="BOOK">
<AU>Espenak L, Adler A, Lowen A</AU>
<SO>Dance Therapy - Theory and Application</SO>
<YR>1981</YR>
<PB>Charles C Thomas</PB>
<CY>Springfield, IL</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Exiner-1994" MODIFIED="2013-10-02 15:27:37 +0100" MODIFIED_BY="Lelia Duley" NAME="Exiner 1994" TYPE="BOOK">
<AU>Exiner J, Kelynack D</AU>
<SO>Dance Therapy Redefined - a Body Approach to Therapeutic Dance</SO>
<YR>1994</YR>
<PB>Charles C Thomas</PB>
<CY>Springfield, IL</CY>
<IDENTIFIERS MODIFIED="2008-11-11 16:49:05 +0000" MODIFIED_BY="Lelia Duley">
<IDENTIFIER MODIFIED="2008-11-11 16:49:05 +0000" MODIFIED_BY="Lelia Duley" TYPE="OTHER" VALUE="ISBN 0-398-05913-6"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fortinash-2000" MODIFIED="2013-10-02 15:27:46 +0100" MODIFIED_BY="Lelia Duley" NAME="Fortinash 2000" TYPE="BOOK">
<AU>Fortinash KM, Holoday-Worret PA</AU>
<SO>Psychiatric Mental Health Nursing</SO>
<YR>2000</YR>
<PB>Mosby</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furukawa-2006" MODIFIED="2012-07-18 12:25:45 +0100" MODIFIED_BY="[Empty name]" NAME="Furukawa 2006" TYPE="JOURNAL_ARTICLE">
<AU>Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N</AU>
<TI>Imputing missing standard deviations in meta-analyses can provide accurate results</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>7</NO>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" MODIFIED="2008-11-11 16:08:18 +0000" MODIFIED_BY="Lelia Duley" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2012-07-18 12:25:45 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" MODIFIED="2008-11-12 12:25:26 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]</TI>
<SO>www.cochrane.org/resources/handbook/hbook.htm</SO>
<YR>(accessed 04 February 2006)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-07-18 12:26:35 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org.</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hutton-2009" MODIFIED="2013-10-02 15:28:04 +0100" MODIFIED_BY="[Empty name]" NAME="Hutton 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hutton JL</AU>
<TI>Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials</TI>
<SO>British Journal of Haematology</SO>
<YR>2009</YR>
<VL>146</VL>
<NO>1</NO>
<PG>27-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1986" MODIFIED="2012-07-18 12:25:45 +0100" MODIFIED_BY="[Empty name]" NAME="Kay 1986" TYPE="BOOK">
<AU>Kay SR, Opler LA, Fiszbein A</AU>
<SO>Positive and Negative Syndrome Scale (PANSS) Manual</SO>
<YR>1986</YR>
<PB>North Tonawanda, NY: Multi-Health Systems</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005" MODIFIED="2012-07-18 12:25:45 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR</AU>
<TI>What does the PANSS mean?</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>79</VL>
<NO>2-3</NO>
<PG>231-8</PG>
<IDENTIFIERS MODIFIED="2012-07-18 12:25:43 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15982856"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005a" MODIFIED="2012-07-18 12:25:45 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>Clinical implications of brief psychiatric rating scale scores</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>187</VL>
<PG>366-71</PG>
<IDENTIFIERS MODIFIED="2012-07-18 12:25:43 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16199797"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2007" MODIFIED="2012-07-18 12:25:45 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2007" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Engel RR, Bauml J, Davis JM</AU>
<TI>Is the superior efficacy of new generation antipsychotics an artifact of LOCF?</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>1</NO>
<PG>183-91</PG>
<IDENTIFIERS MODIFIED="2012-07-18 12:25:43 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16905632"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" MODIFIED="2008-11-11 16:08:18 +0000" MODIFIED_BY="Lelia Duley" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McGrath-2000" MODIFIED="2013-05-16 14:10:14 +0100" MODIFIED_BY="[Empty name]" NAME="McGrath 2000" TYPE="COCHRANE_REVIEW">
<AU>McGrath J, Hayes Robyn L</AU>
<TI>Cognitive rehabilitation for people with schizophrenia and related conditions</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS MODIFIED="2013-05-16 14:10:04 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD000968"/>
<IDENTIFIER TYPE="OTHER" VALUE="CD000968"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-M_x00f6_ssler-2011" MODIFIED="2013-05-16 14:12:25 +0100" MODIFIED_BY="[Empty name]" NAME="Mössler 2011" TYPE="COCHRANE_REVIEW">
<AU>Mössler K, Chen X, Heldal TO, Gold C</AU>
<TI>Music therapy for people with schizophrenia and schizophrenia-like disorders</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>12</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS MODIFIED="2013-05-16 14:12:04 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD004025.pub3"/>
<IDENTIFIER TYPE="OTHER" VALUE="CD004025"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" MODIFIED="2012-07-18 12:25:45 +0100" MODIFIED_BY="[Empty name]" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The brief psychiatric rating scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Payne-2006" MODIFIED="2013-10-02 15:28:19 +0100" MODIFIED_BY="Lelia Duley" NAME="Payne 2006" TYPE="BOOK">
<AU>Payne H</AU>
<SO>Dance Movement Therapy - Theory, Research and Practice</SO>
<YR>2006</YR>
<EN>2nd</EN>
<PB>Routledge</PB>
<CY>Sussex</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Priebe-1995" MODIFIED="2013-09-23 10:29:41 +0100" MODIFIED_BY="Lelia Duley" NAME="Priebe 1995" TYPE="JOURNAL_ARTICLE">
<AU>Priebe S, Gruyters T, Heinze M, Hoffmann C, Jakel A</AU>
<TI>Subjective criteria in psychiatric care - methods of assessment for research and routine care</TI>
<SO>Psychiatrische Praxis</SO>
<YR>1995</YR>
<VL>22</VL>
<PG>140-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Priebe-1999" MODIFIED="2008-11-11 16:08:18 +0000" MODIFIED_BY="Lelia Duley" NAME="Priebe 1999" TYPE="JOURNAL_ARTICLE">
<AU>Priebe S, Huxley P, Knight S, Evans S</AU>
<TI>Application and results of the Manchester Short Assessment of Quality of Life</TI>
<SO>International Journal of Social Psychiatry</SO>
<YR>1999</YR>
<VL>45</VL>
<PG>7-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ruddy-2005" MODIFIED="2013-05-16 13:49:03 +0100" MODIFIED_BY="[Empty name]" NAME="Ruddy 2005" TYPE="COCHRANE_REVIEW">
<AU>Ruddy R, Milnes D</AU>
<TI>Art therapy for schizophrenia or schizophrenia-like illnesses</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>4</NO>
<PG>CD003728</PG>
<IDENTIFIERS MODIFIED="2013-03-18 17:02:21 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-18 17:02:21 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003728.pub2"/>
<IDENTIFIER TYPE="PUBMED" VALUE="16235338"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2008" MODIFIED="2012-07-18 12:25:45 +0100" MODIFIED_BY="[Empty name]" NAME="Schünemann 2008" TYPE="BOOK_SECTION">
<AU>Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al</AU>
<TI>Chapter 12: Interpreting results and drawing conclusions</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<PG>359-83</PG>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1970" MODIFIED="2013-10-02 15:28:35 +0100" MODIFIED_BY="[Empty name]" NAME="Simpson 1970" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Angus JW</AU>
<TI>A rating scale for extrapyramidal side effects</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1970</YR>
<VL>212</VL>
<PG>11-9</PG>
<IDENTIFIERS MODIFIED="2013-01-14 05:53:40 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" MODIFIED="2008-11-12 11:54:38 +0000" MODIFIED_BY="[Empty name]" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>1-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-V_x00e4_lim_x00e4_ki-2012" MODIFIED="2013-10-02 15:28:51 +0100" MODIFIED_BY="[Empty name]" NAME="Välimäki 2012" TYPE="COCHRANE_PROTOCOL">
<AU>Välimäki M, Hätönen H, Adams CE, Arifulla D, Kostiainen J, Kostamo P</AU>
<TI>Information and communication technology-based cognitive remediation for supporting treatment compliance for people with serious mental illness</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>5</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS MODIFIED="2013-05-16 14:06:08 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD009766"/>
<IDENTIFIER TYPE="OTHER" VALUE="CD009766"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Xia-2009" MODIFIED="2012-07-18 12:25:45 +0100" MODIFIED_BY="[Empty name]" NAME="Xia 2009" TYPE="JOURNAL_ARTICLE">
<AU>Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al</AU>
<TI>Loss to outcomes stakeholder survey: the LOSS study</TI>
<SO>Psychiatric Bulletin</SO>
<YR>2009</YR>
<VL>33</VL>
<NO>7</NO>
<PG>254-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xia-2011" MODIFIED="2013-05-16 14:08:42 +0100" MODIFIED_BY="[Empty name]" NAME="Xia 2011" TYPE="COCHRANE_REVIEW">
<AU>Xia J, Merinder LB, Belgamwar Madhvi R</AU>
<TI>Psychoeducation for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>6</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS MODIFIED="2013-05-16 14:08:13 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD002831.pub2"/>
<IDENTIFIER TYPE="OTHER" VALUE="CD002831"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-10-02 15:29:13 +0100" MODIFIED_BY="Heather Maxwell">
<REFERENCE ID="REF-Xia-2009a" MODIFIED="2013-10-02 15:29:13 +0100" MODIFIED_BY="Heather Maxwell" NAME="Xia 2009a" TYPE="COCHRANE_REVIEW">
<AU>Xia J, Grant TJ</AU>
<TI>Dance therapy for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-09-23 10:11:33 +0100" MODIFIED_BY="Heather Maxwell">
<IDENTIFIER MODIFIED="2013-09-23 10:11:33 +0100" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD006868.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2008-04-27 16:56:51 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-10-02 15:15:58 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-09-23 10:37:57 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-09-23 10:37:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rohricht-2006">
<CHAR_METHODS MODIFIED="2013-01-11 08:35:14 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, opening sealed envelope by a blinded person.<BR/>Blinding: single (assessor).<BR/>Duration:10 weeks treatment + 4 months follow-up.<BR/>Setting: community, London.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-23 10:37:13 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-IV).<BR/>Age: 20-55 years.<BR/>N = 45.<BR/>Sex: male = 12 and female = 12 (BPT group); male = 10 and female = 11(SC group).<BR/>Length of illness: 12.1 ± 10.5 years (BPT group); 10.8 ± 7.3 years (SC group).<BR/>Exclusion criteria: evidence of organic brain disease, severe/chronic physical illness, substance misuse.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-23 10:37:57 +0100" MODIFIED_BY="[Empty name]">
<P>1. Body-oriented psychological therapy (BPT) + routine care: including 5 stages: a) opening circle, describe feelings and energy level; b) warm-up section, standing in a circle and warm-up using different body parts and movements; c) structured task section, mirroring each other's movement, creating body image sculpture in partners; d) creative movement section, group mirroring, creating group sculptures. reflecting on how this feels; e) closing circle, reflecting on group experience, re-focusing on self with body-oriented exercises such as self-touch, verbal integration. Frequency: 60-90 minutes/session, 20 sessions over 10 weeks. N = 24.</P>
<P>2. Supportive counselling (SC) + routine care: therapist facilitated a safe and supportive atmosphere and gave the participants opportunity to talk about specific difficulties. The group then engaged in discussing their experience and trying to identify the contributing factors to the problems. Main strategy used is problem solving strategy. Frequency: 60-90 minutes/session, 20 sessions over 10 weeks. N = 21.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-06 07:20:47 +0000" MODIFIED_BY="Lelia Duley">
<P>Leaving the study early.<BR/>Mental state: PANSS, PANSS symptom reduction rate.<BR/>Satisfaction with treatment: CAT, MANSA.<BR/>Adverse events: EPS.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-16 13:56:48 +0100" MODIFIED_BY="Lelia Duley"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>DSM-IV: Diagnostic Statistical Manual, version 4<BR/>PANSS: Positive and Negative Syndrome Scale<BR/>CAT: Client's Assessment of Treatment Scale<BR/>EPS: Extrapyramidal Symptom Rating Scale<BR/>MANSA: Manchester Short Assessment of Quality of life</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-10-02 15:15:58 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-06-19 03:50:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Apter-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 03:50:54 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: people with schizophrenia.</P>
<P>Interventions: individual dance therapy vs group dance therapy vs control.</P>
<P>Outcomes: no useable data- no mean or SD reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 15:15:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISRCTN-2012a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 15:15:58 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised<BR/>Participants: people with schizophrenia.</P>
<P>Interventions:body-oriented psychological therapy (BPT) vs physical activities (PA)</P>
<P>Outcomes: ongoing study, no data reported.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-22 07:47:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Killaspy-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-22 07:47:38 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: people with schizophrenia aged over 18 years.</P>
<P>Interventions: art therapy plus standard care vs activity group plus standard care vs standard care alone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-24 03:04:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Qu-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-24 03:04:08 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised (random number table).</P>
<P>Participants: people with schizophrenia.</P>
<P>Interventions: cognitive remediation therapy vs music therapy plus dance therapy.</P>
<P>Outcomes: no individual useable data for dance therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-19 03:51:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Su-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-19 03:51:54 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: people with schizophrenia.</P>
<P>Interventions: dance therapy.</P>
<P>Outcomes: no useable data- no mean or SD reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-02 15:15:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tan-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-02 15:15:58 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised (random number table).</P>
<P>Participants:chronic inpatients with schizophrenia.</P>
<P>Intervention: cognitive remediation therapy vs computerised cognitive remediation therapy vs work and amusement therapy (music therapy and dance therapy).</P>
<P>Outcomes: no individual useable data for dance therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-11 08:31:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tang-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-11 08:31:51 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-09 12:49:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-09 12:49:44 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-16 13:41:52 +0100" MODIFIED_BY="Lelia Duley" STUDY_ID="STD-Yang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-16 13:41:52 +0100" MODIFIED_BY="Lelia Duley">
<P>Allocation: randomised.</P>
<P>Participants: people with schizophrenia.</P>
<P>Interventions: psycho-education vs standard care (not dance therapy).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-11 08:32:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yao-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-11 08:32:26 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-11 08:32:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhou-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-11 08:32:34 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>SD: standard deviation<BR/>vs: versus</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-06-20 05:25:27 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-10-02 15:15:58 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2013-10-02 15:15:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISRCTN-2012">
<CHAR_STUDY_NAME MODIFIED="2013-10-02 15:15:58 +0100" MODIFIED_BY="[Empty name]">
<P>Effectiveness and cost-effectiveness of body psychotherapy in the treatment of negative symptoms of schizophrenia: a multicentre randomised controlled trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-08-07 07:46:13 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised<BR/>Duration:10 weeks treatment + 6 months follow-up.<BR/>Setting: community, London, UK.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-07 07:46:28 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-IV).<BR/>Age: 18-65 years.<BR/>Sex: male and female.<BR/>Exclusion criteria: severe physical disability, insufficient command of English, a physical condition that makes participation in either body psychotherapy or the physical activities impossible or potentially harmful.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-07 07:47:05 +0100" MODIFIED_BY="[Empty name]">
<P>1. Body-oriented psychological therapy (BPT): a) Overcoming communication barriers through non-verbal techniques, b) Re-focussing cognitive and emotional awareness towards the body (physical reality, coordination and orientation, c) Stimulating activity and emotional responsiveness, d) Exploring physical potentials, e) Focussing on strength and experiencing the body as a source of creativity, reliability, pleasure and self-expression, f) Modifying dysfunctional self-perception and addressing body-related psychopathological features such as boundary loss, somatic depersonalisation, and body schema disturbances. Frequency: 90 minutes/session, 20 sessions over 10 weeks.</P>
<P>2. Physical activities(PA): PA will be described to patients as a fitness and physical health intervention and consist of pilates exercises and follow the established guidelines for such groups. Frequency: 90 minutes/session, 20 sessions over 10 weeks.<BR/>3. Target number of participants: 256</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-23 08:50:02 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: level of negative symptoms as assessed on the Positive and Negative Symptom Scale of Schizophrenia (PANSS). All outcomes will be measured at pre-treatment baseline, at the end of treatment and again 6 months after treatment.</P>
<P>Secondary outcome:</P>
<P>1. Levels of general psychopathology and positive symptoms (PANSS)<BR/>2. Subjective quality of life (Manchester Short Assessment of Quality of Life)<BR/>3. Extrapyramidal symptoms (Simpson-Angus Scale)<BR/>4. Treatment satisfaction (Client Satisfaction Questionnaire)<BR/>5. Objective social situation (SIX), which combines objective indicators of independent accommodation, employment and having a partner/friend<BR/>6. Instrumental Activities of Daily Living Scale (IADL)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-08-07 07:47:49 +0100" MODIFIED_BY="[Empty name]">
<P>01/09/2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-05-16 13:42:13 +0100" MODIFIED_BY="[Empty name]">
<P>Professor Stefan Priebe, Unit for Social and Community Psychiatry Newham Centre for Mental Health Glen Road, London, UK. s.priebe@qmul.ac.uk</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-04-23 08:50:07 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<FOOTNOTES>
<P>DSM-IV: Diagnostic Statistical Manual, version 4</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-03-25 10:47:13 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-03-25 10:47:03 +0000" MODIFIED_BY="Lelia Duley" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-25 10:47:03 +0000" MODIFIED_BY="Lelia Duley" RESULT="UNKNOWN" STUDY_ID="STD-Rohricht-2006">
<DESCRIPTION>
<P>Randomised in blocks, no details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-09-22 14:53:32 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 14:53:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rohricht-2006">
<DESCRIPTION>
<P>Sealed envelope.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2008-11-11 13:53:44 +0000" MODIFIED_BY="Lelia Duley" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-11-11 13:53:44 +0000" MODIFIED_BY="Lelia Duley" RESULT="UNKNOWN" STUDY_ID="STD-Rohricht-2006">
<DESCRIPTION>
<P>Single, but not tested.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2008-11-12 14:03:19 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1" REF_IDS="CMP-001.02 CMP-001.03 CMP-001.05 CMP-001.04 CMP-001.07 CMP-001.08 CMP-001.06">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-12 14:03:19 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rohricht-2006">
<DESCRIPTION>
<P>40% participants lost at follow-up, not addressed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2008-09-22 14:53:39 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-22 14:53:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rohricht-2006">
<DESCRIPTION>
<P>No selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-03-25 10:47:13 +0000" MODIFIED_BY="Lelia Duley" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-25 10:47:13 +0000" MODIFIED_BY="Lelia Duley" RESULT="YES" STUDY_ID="STD-Rohricht-2006">
<DESCRIPTION>
<P>Study supported by East London &amp; The City Mental Health Trust and an unconditional grant by Pfizer and Wyeth.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-10-02 15:25:25 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-10-02 15:25:25 +0100" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2013-10-02 15:25:25 +0100" MODIFIED_BY="Grade Profiler">DANCE THERAPY compared with STANDARD CARE for schizophrenia</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>DANCE THERAPY compared to STANDARD CARE for schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with schizophrenia<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> DANCE THERAPY<BR/>
<B>Comparison: </B>STANDARD CARE</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>STANDARD CARE</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>DANCE THERAPY</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Service utilisation-days in hospital</B>
</P>
</TD>
<TD>
<P>No data available</P>
</TD>
<TD>
<P>No data available</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Clinical global response-leaving the study early (short term)</B>
<BR/>Follow-up: 4 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>95 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>42 per 1000</B>
<BR/>(4 to 428)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.44 </B>
<BR/>(0.04 to 4.49)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>45<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Clinical global response-leaving the study early (long term)</B>
<BR/>Follow-up: 4 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>429 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>291 per 1000</B>
<BR/>(133 to 647)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.68 </B>
<BR/>(0.31 to 1.51)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>45<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: 2a. Negative symptoms - average score (PANSS negative endpoint, high = poor)</B>
<BR/>Follow-up: 4 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean mental state: 2a. negative symptoms - average score (PANSS negative endpoint, high = poor) in the control groups was<BR/>
<B>23.3 </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean mental state: 2a. negative symptoms - average score (PANSS negative endpoint, high = poor) in the intervention groups was<BR/>
<B>4.4 lower</B>
<BR/>(8.15 to 0.65 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>43<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: 2b. Negative symptoms - not improved (PANSS negative symptom reduction less than 20-40%)</B>
<BR/>Follow-up: 4 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>810 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>502 per 1000</B>
<BR/>(316 to 785)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.62 </B>
<BR/>(0.39 to 0.97)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>45<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Satisfaction with care: Average endpoint score (CAT, high = good)</B>
<BR/>Follow-up: 4 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean satisfaction with care: average endpoint score (CAT, high = good) in the control groups was<BR/>
<B>6.4 </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean satisfaction with care: average endpoint score (CAT, high = good) in the intervention groups was<BR/>
<B>0.4 higher</B>
<BR/>(0.78 lower to 1.58 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>42<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Quality of life Manchester Short Assessment (MANSA, high = good)</B>
<BR/>Follow-up: 4 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean quality of life Manchester short assessment (MANSA, high = good) in the control groups was<BR/>
<B>4.1 </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean quality of life Manchester short assessment (MANSA, high = good) in the intervention groups was</P>
<P>
<B>0 higher</B>
<BR/>(0.48 lower to 0.48 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>39<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Risk of bias: rated-'serious': Randomised in blocks, no details reported.<BR/>
<SUP>2</SUP> Risk of bias: rated-'serious': Single blind, but not tested.<BR/>
<SUP>3</SUP> Risk of bias: rated-'serious': Over 40% of the participants were lost to follow-up in control group</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-10-02 15:15:58 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-09-23 10:45:50 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-05-16 14:14:41 +0100" MODIFIED_BY="[Empty name]">Reviews in which excluded studies may be included</TITLE>
<TABLE COLS="3" ROWS="6">
<TR>
<TH VALIGN="TOP">
<P>Title</P>
</TH>
<TH VALIGN="TOP">
<P>References</P>
</TH>
<TH VALIGN="TOP">
<P>Exsiting related review</P>
</TH>
</TR>
<TR>
<TD>
<P>Art therapy for schizophrenia</P>
</TD>
<TD>
<P>
<LINK REF="STD-Killaspy-1997" TYPE="STUDY">Killaspy 1997</LINK>
</P>
</TD>
<TD>
<P>
<LINK REF="REF-Ruddy-2005" TYPE="REFERENCE">Ruddy 2005</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Cognitive remediation therapy for schizophrenia</P>
</TD>
<TD>
<P>
<LINK REF="STD-Tan-2010" TYPE="STUDY">Tan 2010</LINK>
</P>
</TD>
<TD>
<P>
<LINK REF="REF-McGrath-2000" TYPE="REFERENCE">McGrath 2000</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Information and communication technology-based cognitive remediation for supporting treatment compliance for people with serious mental illness</P>
</TD>
<TD>
<P>
<LINK REF="STD-Tan-2010" TYPE="STUDY">Tan 2010</LINK>
</P>
</TD>
<TD>
<P>
<LINK REF="REF-V_x00e4_lim_x00e4_ki-2012" TYPE="REFERENCE">Välimäki 2012</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Music therapy plus dance therapy for schizophrenia</P>
</TD>
<TD>
<P>
<LINK REF="STD-Qu-2007" TYPE="STUDY">Qu 2007</LINK>; <LINK REF="STD-Tang-2011" TYPE="STUDY">Tang 2011</LINK>; <LINK REF="STD-Tan-2010" TYPE="STUDY">Tan 2010</LINK>
</P>
</TD>
<TD>
<P>
<LINK REF="REF-M_x00f6_ssler-2011" TYPE="REFERENCE">Mössler 2011</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Psychoeducation for schizophrenia</P>
</TD>
<TD>
<P>
<LINK REF="STD-Yang-2005" TYPE="STUDY">Yang 2005</LINK>
</P>
</TD>
<TD>
<P>
<LINK REF="REF-Xia-2011" TYPE="REFERENCE">Xia 2011</LINK>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2013-10-02 15:15:58 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2013-03-25 10:21:33 +0000" MODIFIED_BY="[Empty name]">Suggested design for a trial of dance therapy</TITLE>
<TABLE COLS="2" ROWS="5">
<TR>
<TH>
<P>Methods</P>
</TH>
<TD>
<P>Allocation: centralised sequence generation with table of random numbers or computer-generated code, stratified by severity of illness, sequence concealed till interventions assigned.<BR/>Blinding: those recruiting and assigning participants, those assessing outcomes, all blind to allocated group, blinding tested.<BR/>Duration: minimum of 52 weeks.</P>
</TD>
</TR>
<TR>
<TH>
<P>Participants</P>
</TH>
<TD>
<P>Diagnosis: schizophrenia, if operational criteria used these should be in the context of routine care.<BR/>N = 300*.<BR/>Age: adults.<BR/>Sex: men and women.<BR/>Setting: anywhere dance therapy is available for this group.</P>
</TD>
</TR>
<TR>
<TH>
<P>Interventions</P>
</TH>
<TD>
<P>1. Dance therapy: the nature and frequency of this approach should be clearly described. N = 150.<BR/>2. Routine therapy. N = 150. This also should be clearly described.</P>
</TD>
</TR>
<TR>
<TH>
<P>Outcomes</P>
</TH>
<TD>
<P>Quality of life: healthy days,** SF-36***.<BR/>Service outcomes: days in hospital, time attending psychiatric outpatient clinic.<BR/>Satisfaction with care: patients/carers.<BR/>Global state: CGI.***<BR/>Mental state: CGI.<BR/>Social functioning: to include occupational status.<BR/>Adverse effects: including mortality.<BR/>Economic data.</P>
</TD>
</TR>
<TR>
<TH>
<P>Notes</P>
</TH>
<TD>
<P>* size of study to detect a 10% difference in improvement with 80% certainty.<BR/>
<BR/>** Primary outcome.<BR/>
<BR/>*** If scales are used to measure outcome then there should be binary cut off points, defined before study starts, of clinically important improvement.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CGI: Clinical Global Impression</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-10-02 15:30:32 +0100" MODIFIED_BY="Lelia Duley">
<COMPARISON ID="CMP-001" MODIFIED="2013-10-02 15:30:32 +0100" MODIFIED_BY="Lelia Duley" NO="1">
<NAME>DANCE THERAPY vs STANDARD CARE</NAME>
<DICH_OUTCOME CHI2="0.12689260740277197" CI_END="1.3593449993200695" CI_START="0.2979072111116065" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6363636363636365" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.13332969388179544" LOG_CI_START="-0.5259189841697317" LOG_EFFECT_SIZE="-0.19629464514396813" METHOD="MH" MODIFIED="2008-11-11 16:37:58 +0000" MODIFIED_BY="Lelia Duley" NO="1" P_CHI2="0.721675974376822" P_Q="0.7248260140532955" P_Z="0.24313832011860081" Q="0.12391556072692862" RANDOM="NO" SCALE="44.22707657545601" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="48" TOTAL_2="42" WEIGHT="200.0" Z="1.16717847953023">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Dance Therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard Care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Dance Therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Standard Care</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.487245911235435" CI_START="0.042655618565665326" DF="0" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.6519798705061411" LOG_CI_START="-1.3700237557894768" LOG_EFFECT_SIZE="-0.3590219426416679" MODIFIED="2008-11-11 15:04:22 +0000" MODIFIED_BY="Lelia Duley" NO="1" P_CHI2="1.0" P_Z="0.4864208963476625" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="21" WEIGHT="100.0" Z="0.6960126758292938">
<NAME>short term</NAME>
<DICH_DATA CI_END="4.487245911235435" CI_START="0.042655618565665326" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6519798705061411" LOG_CI_START="-1.3700237557894768" LOG_EFFECT_SIZE="-0.3590219426416679" ORDER="15" O_E="0.0" SE="1.1877349391654206" STUDY_ID="STD-Rohricht-2006" TOTAL_1="24" TOTAL_2="21" VAR="1.4107142857142856" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5076151868920133" CI_START="0.30721093036502123" DF="0" EFFECT_SIZE="0.6805555555555556" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.1782905036450245" LOG_CI_START="-0.5125633364505342" LOG_EFFECT_SIZE="-0.16713641640275478" MODIFIED="2008-11-11 15:04:12 +0000" MODIFIED_BY="Lelia Duley" NO="2" P_CHI2="1.0" P_Z="0.3429575967849344" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="21" WEIGHT="100.00000000000001" Z="0.9483376588286114">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.5076151868920133" CI_START="0.30721093036502123" EFFECT_SIZE="0.6805555555555556" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.1782905036450245" LOG_CI_START="-0.5125633364505342" LOG_EFFECT_SIZE="-0.16713641640275478" ORDER="16" O_E="0.0" SE="0.40581096545379314" STUDY_ID="STD-Rohricht-2006" TOTAL_1="24" TOTAL_2="21" VAR="0.16468253968253968" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="10.803473845863872" CI_START="-11.803473845863872" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2013-09-23 11:01:07 +0100" MODIFIED_BY="Lelia Duley" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.9309120291557078" Q="0.0" RANDOM="NO" SCALE="34.75" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="19" UNITS="" WEIGHT="100.0" Z="0.08669741759331967">
<NAME>Mental state: 1. Total - average score (PANSS total endpoint, high = poor)</NAME>
<GROUP_LABEL_1>Dance Therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard Care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Dance Therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Standard Care</GRAPH_LABEL_2>
<CONT_DATA CI_END="10.803473845863872" CI_START="-11.803473845863872" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="71.4" MEAN_2="71.9" MODIFIED="2008-04-27 19:01:46 +0100" MODIFIED_BY="[Empty name]" ORDER="8" SD_1="15.7" SD_2="20.9" SE="5.767184466155618" STUDY_ID="STD-Rohricht-2006" TOTAL_1="24" TOTAL_2="19" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.671562608002051" CI_START="-0.6715626080020511" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2013-09-23 11:01:21 +0100" MODIFIED_BY="Lelia Duley" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.12235802920633752" Q="0.0" RANDOM="NO" SCALE="9.72" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="19" UNITS="" WEIGHT="100.0" Z="1.5449513589885806">
<NAME>Mental state: 2. Positive symptoms - average score (PANSS positive endpoint, high = poor)</NAME>
<GROUP_LABEL_1>Dance Therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard Care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Dance Therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Standard Care</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.671562608002051" CI_START="-0.6715626080020511" EFFECT_SIZE="2.5" ESTIMABLE="YES" MEAN_1="15.3" MEAN_2="12.8" MODIFIED="2008-04-27 19:00:36 +0100" MODIFIED_BY="[Empty name]" ORDER="7" SD_1="5.1" SD_2="5.4" SE="1.6181739220816975" STUDY_ID="STD-Rohricht-2006" TOTAL_1="24" TOTAL_2="19" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.6542006747420008" CI_START="-8.145799325258004" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.400000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2013-09-23 11:01:38 +0100" MODIFIED_BY="Lelia Duley" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.021319948744243224" Q="0.0" RANDOM="NO" SCALE="18.4" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="19" UNITS="" WEIGHT="100.0" Z="2.3022700318795786">
<NAME>Mental state: 3a. Negative symptoms - average score (PANSS negative endpoint, high = poor)</NAME>
<GROUP_LABEL_1>Dance Therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard Care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Dance Therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Standard Care</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.6542006747420008" CI_START="-8.145799325258004" EFFECT_SIZE="-4.400000000000002" ESTIMABLE="YES" MEAN_1="18.9" MEAN_2="23.3" MODIFIED="2008-04-27 18:58:10 +0100" MODIFIED_BY="[Empty name]" ORDER="6" SD_1="4.3" SD_2="7.4" SE="1.9111572226859208" STUDY_ID="STD-Rohricht-2006" TOTAL_1="24" TOTAL_2="19" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9693114376878523" CI_START="0.39356585968214597" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6176470588235294" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.013536662641406894" LOG_CI_START="-0.40498258197526477" LOG_EFFECT_SIZE="-0.20925962230833584" METHOD="MH" MODIFIED="2013-10-02 15:30:32 +0100" MODIFIED_BY="Lelia Duley" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.03612481664085217" Q="0.0" RANDOM="NO" SCALE="11.69" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="21" WEIGHT="100.0" Z="2.0955197276842212">
<NAME>Mental state: 3b. Negative symptoms - not improved (PANSS negative symptom reduction less than 20% - 40%)</NAME>
<GROUP_LABEL_1>Dance Therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard Care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Dance Therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Standard Care</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9693114376878523" CI_START="0.39356585968214597" EFFECT_SIZE="0.6176470588235294" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="-0.013536662641406894" LOG_CI_START="-0.40498258197526477" LOG_EFFECT_SIZE="-0.20925962230833584" MODIFIED="2008-04-27 18:43:06 +0100" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.22993727070525943" STUDY_ID="STD-Rohricht-2006" TOTAL_1="24" TOTAL_2="21" VAR="0.05287114845938376" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="8.467648978906843E-33" CI_END="1.5823523040258387" CI_START="-0.7823523040258398" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3999999999999994" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2013-09-23 11:01:52 +0100" MODIFIED_BY="Lelia Duley" NO="6" P_CHI2="0.0" P_Q="1.0" P_Z="0.5072839662316151" Q="0.0" RANDOM="NO" SCALE="2.96" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="19" UNITS="" WEIGHT="100.0" Z="0.6630727500987619">
<NAME>Satisfaction with care: 1. Average endpoint score (CAT, high = good)</NAME>
<GROUP_LABEL_1>Dance Therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard Care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Dance Therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Standard Care</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.5823523040258387" CI_START="-0.7823523040258398" EFFECT_SIZE="0.39999999999999947" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="6.4" ORDER="9" SD_1="2.0" SD_2="1.9" SE="0.6032520563398528" STUDY_ID="STD-Rohricht-2006" TOTAL_1="23" TOTAL_2="19" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.47562510621612336" CI_START="-0.47562510621612336" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2013-09-23 11:02:08 +0100" MODIFIED_BY="Lelia Duley" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="1.48" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>Quality of life: 1. Average endpoint score (MANSA, high = good)</NAME>
<GROUP_LABEL_1>Dance Therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard Care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Dance Therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Standard Care</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.4756251062161233" CI_START="-0.4756251062161233" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="4.1" ORDER="10" SD_1="0.7" SD_2="0.8" SE="0.24267032964268395" STUDY_ID="STD-Rohricht-2006" TOTAL_1="21" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.08" MODIFIED="2013-09-23 11:02:18 +0100" MODIFIED_BY="[Empty name]" NO="8" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse effects: 1. Average endpoint score (EPS, high = poor, skewed data)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2008-10-23 14:04:34 +0100" MODIFIED_BY="[Empty name]" ORDER="949" STUDY_ID="STD-Rohricht-2006">
<TR>
<TD>
<P>Dance therapy</P>
</TD>
<TD>
<P>1.3</P>
</TD>
<TD>
<P>1.6</P>
</TD>
<TD>
<P>24</P>
</TD>
</TR>
<TR>
<TD>
<P>Control group</P>
</TD>
<TD>
<P>1.6</P>
</TD>
<TD>
<P>2.2</P>
</TD>
<TD>
<P>19</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-05-31 08:03:43 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Dance therapy.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2013-05-16 13:46:23 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Dance therapy</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-05-31 08:03:43 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram to show trial selection</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfIAAAIOCAYAAABDKY8vAAAbxElEQVR42u3d247iyBJA0f7/n57z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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-05-16 13:46:22 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for the included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAARoAAAE4CAIAAAALtavQAAANdUlEQVR42u3dv25kRRbH8ZaQEIED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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-05-16 13:46:22 +0100" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-10-02 15:15:58 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-07-31 13:23:00 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-01-29 11:48:06 +0000" MODIFIED_BY="[Empty name]">Previous plain language summary</TITLE>
<APPENDIX_BODY MODIFIED="2013-07-31 13:23:00 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Dance therapy for schizophrenia</HEADING>
<P> Schizophrenia can be a long-term disabling illness. The most common treatments for people with this condition are medication (antipsychotics) and talking therapies, especially cognitive behavioural therapy and family therapy. These treatments work well for people with 'positive' symptoms (hearing voices and other alterations of the senses) and delusions (distortions in the way the world is seen). However people experiencing 'negative' symptoms (such as flattening of mood, poverty of speech, lack of drive, loss of feeling, social withdrawal and decreased spontaneous movement) do not respond as well. Dance therapy (also called dance movement therapy) uses dance and movement to explore a person&#8217;s emotions in a non-verbal way. The therapist will help the individual to interpret their movement as a link to personal feelings. This review aims to assess how successful this therapy is as a treatment for schizophrenia, when compared to standard care or other interventions. Six studies were identified but five were excluded because there were no reliable data, because they were for a therapy other than dance or because they were not properly randomised. The included study compared 10 weeks of group dance therapy plus standard care, to group supportive counselling plus standard care for the same length of time. It was a community-based project involving 45 people and both groups were followed up after four months. Of the outcomes measured (mental state, satisfaction with care, leaving the study early, quality of life and adverse effects) the majority showed no difference between the two groups. However, when negative symptoms were specifically measured after 10 weeks of treatment, there was a significant improvement in the mental state of the dance therapy group. At the four month follow-up more than 40% of the participants had been lost from both groups, making it impossible to draw any valid conclusions from the outcomes measured. Overall, because of the relatively small number of people, the data from this trial were inconclusive. However a larger randomised trial measuring outcomes such as relapse, admission to hospital, quality of life, leaving the study early, cost of care and satisfaction with treatment would help clarify whether dance therapy is an effective treatment for schizophrenia; especially for negative symptoms that don't respond so well to medication and talking therapies.(Plain language summary prepared for this review by Janey Antoniou of RETHINK, UK <A HREF="http://www.rethink.org">www.rethink.org</A>).</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-01-29 11:50:06 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-07-18 12:21:29 +0100" MODIFIED_BY="[Empty name]">Previous search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-07-18 12:21:34 +0100" MODIFIED_BY="[Empty name]">
<P>1. Cochrane Schizophrenia Group Trials Register (July 2007)</P>
<P>We searched the Cochrane Schizophrenia Group Trials Register (July 2007) using the phrase:</P>
<P>[(* danc* in title, abstract, index terms of REFERENCE) or (danc* in interventions of STUDY)]</P>
<P>This register is compiled by systematic searches of major databases, hand searches and conference proceedings (see <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html">Group Module</A>).<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2013-10-02 15:15:58 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2012-07-18 12:24:14 +0100" MODIFIED_BY="[Empty name]">Previous data collection and analyses</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-02 15:15:58 +0100" MODIFIED_BY="[Empty name]">
<P>1. Extraction<BR/>JX and TG independently extracted data from included studies. JX carried out a separate re-extraction of data to ensure reliability. Again, when disputes arose, we attempted to resolve these by discussion and where further clarification was needed we contacted the authors of trials to provide us with the missing data. While waiting for further information, trials were added to the list of those awaiting assessment.</P>
<P>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for dance therapy.</P>
<P>2. Management<BR/>Data were extracted onto standard, simple forms.</P>
<P>3. Scale-derived data<BR/>We included continuous data from rating scales only if the measuring instrument had been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>) and the instrument is either a self-report or completed by an independent rater or relative (not the therapist).</P>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of risk of bias in included studies  </HEADING>
<P>Again working independently, JX and TG assessed risk of bias using the tool described in The Cochrane Collaboration Handbook (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>). This tool encourages consideration of how the sequence was generated, how allocation was concealed, the integrity of blinding at outcome, the completeness of outcome data, selective reporting and other biases. We would not have included studies where sequence generation was at high risk of bias or where allocation was clearly not concealed.</P>
<P>If disputes arose as to which category a trial has to be allocated, again resolution was made by discussion between the authors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Measures of treatment effect  </HEADING>
<P>1. Binary data<BR/>For binary outcomes we calculated a standard estimation of the fixed-effect risk ratio (RR) and its 95% confidence interval (CI). For statistically significant results we calculated the number needed to treat/harm statistic (NNT/H), and its 95% confidence interval (CI) using <A HREF="http://www.nntonline.net/">Visual Rx</A> taking account of the event rate in the control group.</P>
<P>2. Continuous data<BR/>2.1 Summary statistic<BR/>For continuous outcomes we estimated a fixed-effect weighted mean difference (WMD) between groups. We did not calculate effect size measures.</P>
<P>2.2 Endpoint versus change data<BR/>We preferred to use scale endpoint data, which typically cannot have negative values and is easier to interpret from a clinical point of view. Change data are often not ordinal and are very problematic to interpret. If endpoint data were unavailable, we used change data.</P>
<P>2.3 Skewed data<BR/>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we aimed to apply the following standards to all data before inclusion: (a) standard deviations and means are reported in the paper or obtainable from the authors; (b) when a scale starts from the finite number zero, the standard deviation, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution, (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>); (c) if a scale starts from a positive value (such as PANSS which can have values from 30 to 210), the calculation described above will be modified to take the scale starting point into account. In these cases skew is present if 2SD&gt;(S-S min), where S is the mean score and S min is the minimum score. Endpoint scores on scales often have a finite start and end point and these rules can be applied. When continuous data are presented on a scale which includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not. Skewed data from studies of less than 200 participants were entered as 'other data' rather than into an analysis. Skewed data pose less of a problem when looking at means if the sample size is large and were entered into syntheses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Unit of analysis issues  </HEADING>
<P>1. Cluster trials<BR/>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intraclass correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>; <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>Where clustering was not accounted for in primary studies, we planned to present data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain the intraclass correlation coefficient (ICC) of their clustered data and to adjust for this by using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). If clustering had been incorporated into the analysis of primary studies, we planned to present these data as if from a non-cluster randomised study, but adjusted for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICC [Design effect = 1+(m-1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC had not been reported, we would have assumed it to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>If we had included cluster studies and they had been appropriately analysed taking into account the ICC and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique.</P>
<P>2. Cross-over trials<BR/>A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence on entry to the second phase the participants can differ systematically from their initial state despite a wash-out phase. For the same reason cross-over trials are not appropriate if the condition of interest is unstable (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). As both effects are very likely in schizophrenia, if we had included cross-over trials, we planned to useonly data of the first phase of cross-over studies.</P>
<P>3. Studies with multiple treatment groups<BR/>Where a study involved more than two treatment arms, if relevant, the additional treatment arms were presented in comparisons. Where the additional treatment arms were not relevant, these data would nott have been reproduced.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dealing with missing data  </HEADING>
<P>1. Overall loss of credibility<BR/>At some degree of loss of follow-up, data must lose credibility. We are forced to make a judgment where this is for the very short-term trials likely to be included in this review. Should more than 30% of data be unaccounted for by 24 hours we did not reproduce these data or use them within analyses.</P>
<P>2. Binary<BR/>In the case where attrition for a binary outcome is between 0% and 30% and outcomes of these people are described, we included these data as reported. Where these data were not clearly described, we assumed the worst primary outcome, and rates of adverse effects similar to those who did continue to have their data recorded.</P>
<P>3. Continuous<BR/> In the case where attrition for a continuous outcome is between 0% and 30% and completer-only data were reported, we have reproduced these.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of heterogeneity  </HEADING>
<P>As only one study was included we could not examine heterogeneity.</P>
<P>1. Clinical heterogeneity<BR/>We planned to consider all included studies without any comparison to judge clinical heterogeneity.</P>
<P>2. Statistical<BR/>2.1 Visual inspection<BR/>We planned to visually inspect graphs to investigate the possibility of statistical heterogeneity.</P>
<P>2.2 Employing the I-squared statistic<BR/>This provides an estimate of the percentage of inconsistency thought to be due to chance. An I-squared estimate greater than or equal to 40% would have been interpreted as evidence of high levels of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of reporting biases  </HEADING>
<P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). These are described in section 10.1 of the Cochrane Handbook (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small-study effects. As we only included one study, we did not use funnel plots to investigate the likelihood of overt publication bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data synthesis  </HEADING>
<P>Where possible we employed a fixed-effect model for analyses. We understand that there is no closed argument for preference for use of fixed- or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This does seem true to us, however, random-effects does put added weight onto the smaller of the studies - those trials that are most vulnerable to bias. For this reason we favour using fixed-effect models employing random-effects only when investigating heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis and investigation of heterogeneity  </HEADING>
<P>There were no subgroup analyses planned.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis  </HEADING>
<P>Again, had there been more trials we would have analysed the effect of excluding studies with high attrition rates in a sensitivity analysis. We would have compared primary outcomes for trials where randomisation was implied, rather than described, with those where allocation was clearly at random.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_2" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="2">
<FLOWCHARTBOX TEXT="&lt;p&gt;1 studies included in the meta-analysis&lt;/p&gt;" WIDTH="135">
<FLOWCHARTBOX TEXT="&lt;p&gt;12 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="143">
<FLOWCHARTBOX TEXT="&lt;p&gt;514 records after duplicates removed&lt;/p&gt;" WIDTH="137">
<FLOWCHARTBOX TEXT="&lt;p&gt;1026 records screened&lt;/p&gt;" WIDTH="149">
<FLOWCHARTBOX TEXT="&lt;p&gt;1020 records identified through database searching (2012 update)&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;6 from previous search&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;502 irrelevant records excluded&lt;/p&gt;" WIDTH="208"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;11 full-text articles excluded - 4 not randomised, 4 not dance therapy, 2 no usable data, 1 ongoing study&lt;/p&gt;" WIDTH="198"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>